[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1342
1. Dai CL, Peng SL, Jia CJ, Xu YQ: [Resection of centrally located primary liver cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug;30(4):460-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection of centrally located primary liver cancer].
  • OBJECTIVE: To summarize the experience of hepatectomy for patients with centrally located primary liver cancer.
  • METHODS: The clinical data of patients with centrally and non-centrally located primary liver cancer were retrospectively reviewed.
  • RESULTS: Tumor diameter, Child-Pugh score, indocyanine green retention rate, aspartate aminotransferase, alanine aminotransferase, glutamyltransferase, total bilirubin, direct bilirubin, albumin, prealbumin, cholinesterase, hepatic inflow occlusion time, blood transfusion, postoperative complications, and operative blood loss were not significantly different between patients with centrally and non-centrally located primary liver cancer.
  • Patients with centrally located liver cancer had significantly longer operation duration and hospital stay than patients with non-centrally located liver cancer (P < 0.05).
  • CONCLUSIONS: Hepatectomy is safe and feasible for patients with centrally located primary liver cancer.
  • Appropriate preoperative evaluation and preparation, sufficient knowledge of liver anatomy, and proper selection of hepatic inflow occlusion method are key factors to guarantee the success of the resection.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Liver Function Tests. Male. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / therapy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795621.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


2. Zhou XP, Quan ZW, Cong WM, Yang N, Zhang HB, Zhang SH, Yang GS: Micrometastasis in surrounding liver and the minimal length of resection margin of primary liver cancer. World J Gastroenterol; 2007 Sep 7;13(33):4498-503
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micrometastasis in surrounding liver and the minimal length of resection margin of primary liver cancer.
  • AIM: To describe the distribution of micrometastases in the surrounding liver of patients with primary liver cancer (PLC), and to describe the minimal length of resection margin (RM) for hepatectomy.
  • The resected liver specimens were minutely examined to measure the resection margin and to detect the number of daughter tumor nodules, dominant lesions, and macroscopic tumor thrombi inside the lumens of the major venous system.
  • RESULTS: In the retrospective study, 70 micrometastases were found in surrounding liver in 26 of the 120 cases (21.7%).
  • Two hundred and sixty-seven micrometastases were found in surrounding liver in 14 (77.8%) out of 18 cases with macroscopic tumor thrombi or macrosatellites.
  • CONCLUSION: The required minimal length of RM is 5.5 mm and 6 mm respectively to achieve 99% and 100% micrometastasis clearance in surrounding liver of PLC patients without macroscopic tumor thrombi or macrosatellites, and should be greater than 18.5 mm to obtain 99% micrometastasis clearance in surrounding liver of patients with macroscopic tumor thrombi or macrosatellites.
  • [MeSH-major] Hepatectomy. Liver. Liver Neoplasms. Neoplasm Metastasis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724808.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4611585
  •  go-up   go-down


3. Yan LN, Chen XL, Li ZH, Li B, Lu SC, Wen TF, Zeng Y, Yiao HH, Yang JY, Wang WT, Xu MQ: Perioperative management of primary liver cancer. World J Gastroenterol; 2007 Apr 7;13(13):1970-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative management of primary liver cancer.
  • AIM: To minimize the complications and mortality and improve the survival in primary liver cancer (PLC) patients undergoing hepatic resection.
  • The half liver vascular occlusion protocol (n = 523) versus the Pringle method (n = 476) showed that the former significantly reduced the postoperative complications (25.8% vs 11.9%) and mortality (2.3% vs 0.6%) respectively, and cut mean hospital stay was 3.5 d.
  • CONCLUSION: RTI is of value in predicting hepatic functional reserve, half liver occlusion could protect the residual liver function, and AKBR measurement is a simple and accurate means of assessing the state of postoperative metabolism.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Perioperative Care / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Energy Metabolism / physiology. Female. Humans. Ketone Bodies / blood. Liver / metabolism. Liver / physiopathology. Liver / surgery. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Sep;182(3):265-7 [11587690.001]
  • [Cites] J Physiol Paris. 2001 Jan-Dec;95(1-6):413-6 [11595468.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2000 Jul;38(7):520-2 [11832098.001]
  • [Cites] Medicina (Kaunas). 2004;40(2):127-34 [15007271.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1990 Jun;87(6):1401-9 [2170713.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1990 May;28(5):295-7, 318-9 [2086101.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Jan;37(1):88-92 [16468651.001]
  • [Cites] Chin Med J (Engl). 1992 Aug;105(8):684-8 [1458973.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1994 Jan;32(1):35-6 [8045199.001]
  • [Cites] Am J Epidemiol. 1999 Jun 1;149(11):1010-5 [10355376.001]
  • [Cites] Korean J Gastroenterol. 2005 Apr;45(4):217-26 [15843747.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):63-8 [16368492.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1991 Feb;29(2):84-6, 141 [1650683.001]
  • (PMID = 17461499.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ketone Bodies
  • [Other-IDs] NLM/ PMC4146975
  •  go-up   go-down


Advertisement
4. Gayet B, Cavaliere D, Castel B, Carlini F, Vibert E, Mal F: [Laparoscopic liver surgery for metastases of colorectal cancer: analysis of a monocentric experience]. Suppl Tumori; 2005 May-Jun;4(3):S135-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic liver surgery for metastases of colorectal cancer: analysis of a monocentric experience].
  • [Transliterated title] Laparoscopic liver surgery for metastases of colorectal cancer: analysis of a monocentric experience.
  • BACKGROUND: Advances in laparoscopic techniques, refinements of instruments and growth of practical experience in liver surgery during the last decade have prompted some surgeons to develop the laparoscopic approach for hepatic metastases of colorectal cancer (MCRC).
  • AIMS: Primary end points of this clinical study were safety and effectiveness of laparoscopic hepatectomy for MCRC, including early postoperative results and long-term outcomes (overall survival and disease-free survival).
  • Resection was considered when all liver metastases can be totally removed with clear margins, and in absence of nonresectable extrahepatic diseases.
  • Five patients who had a recurrence of metastatic liver disease were referred to a second laparoscopic resection.
  • CONCLUSION: This clinical study suggests that laparoscopic liver surgery for metastatic colorectal cancer can be accomplished safely, in selected patients and by experienced surgeons, with good early results and without detrimental consequences on survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Laparoscopy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437952.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Zhang CY, Huang TR, Yu JH, Zhang ZQ, Li JL, Deng W, Ye SY, Zhou DN, He ZF: Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer; 2010 May;29(5):545-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China.
  • BACKGROUND AND OBJECTIVE: In Guangxi province, from 1970s to 1990s, the mortality of primary liver cancer (PLC) ranked the first among a variety of malignant tumors.
  • [MeSH-major] Liver Neoplasms / epidemiology. Liver Neoplasms / mortality. Mortality / trends
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. China / epidemiology. Female. Humans. Infant. Male. Middle Aged. Sex Distribution. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426906.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Jim MA, Perdue DG, Richardson LC, Espey DK, Redd JT, Martin HJ, Kwong SL, Kelly JJ, Henderson JA, Ahmed F: Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer; 2008 Sep 1;113(5 Suppl):1244-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver cancer incidence among American Indians and Alaska Natives, US, 1999-2004.
  • BACKGROUND: American Indians and Alaska Natives (AI/AN) experience higher morbidity and mortality from primary liver cancer than other United States (US) populations, but racial misclassification in medical records results in underestimates of disease burden.
  • METHODS: To reduce misclassification, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results data were linked with Indian Health Service (IHS) enrollment records to compare primary liver cancer incidence and stage at diagnosis between AI/AN and non-Hispanic whites (NHW) living within the regionalized IHS Contract Health Service Delivery Area counties.
  • Liver cancer incidence rates among AI/AN males and females were higher than those among NHW males and females for all regions except for the East.
  • CONCLUSIONS: Reducing racial misclassification revealed higher disparities in primary liver cancer incidence between NHW and AI/AN populations than previously reported.
  • Further description of the reasons for regional differences in this disparity is needed, as are programs to reduce risk factors and to diagnose primary liver cancer at earlier, more treatable stages.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089139; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Weitz J, Klimstra DS, Cymes K, Jarnagin WR, D'Angelica M, La Quaglia MP, Fong Y, Brennan MF, Blumgart LH, Dematteo RP: Management of primary liver sarcomas. Cancer; 2007 Apr 1;109(7):1391-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary liver sarcomas.
  • BACKGROUND: Primary hepatic sarcoma is a rare entity.
  • METHODS: Between January 1981 and December 2004, 30 patients with primary sarcoma of the liver and 5 patients with primary carcinosarcoma of the liver were treated.
  • RESULTS: Of the 30 patients with primary hepatic sarcoma (10 epithelioid hemangioendothelioma, 5 embryonal sarcoma, 5 angiosarcoma, 3 solitary fibrous tumor, and 7 other types), 11 underwent R0-resection and had a 5-year disease-specific survival of 64%.
  • The prognosis for patients with primary carcinosarcoma of the liver was poor, with all but 1 patient dying within a year and no 3-year survivors.
  • CONCLUSIONS: The outcome of patients with primary hepatic sarcoma depends primarily on tumor histology and the ability to achieve complete tumor resection.
  • [MeSH-major] Liver Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / therapy. Child. Female. Fibrosarcoma / therapy. Hemangioendothelioma, Epithelioid / therapy. Hemangiosarcoma / therapy. Humans. Leiomyosarcoma / therapy. Male. Middle Aged. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17315167.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pineau P, Tiollais P: [Hepatitis B vaccination: a major player in the control of primary liver cancer]. Pathol Biol (Paris); 2010 Dec;58(6):444-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatitis B vaccination: a major player in the control of primary liver cancer].
  • [Transliterated title] La vaccination: atout majeur dans la lutte contre le cancer du foie induit par le virus de l'hépatite B.
  • In worst cases, chronic hepatitis B ultimately leads to primary liver cancer.
  • Finally, lack of early immunization of newborns in developing countries still represents a major limitation to the progresses against liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis B Vaccines. Liver Neoplasms / prevention & control. Vaccination
  • [MeSH-minor] Adult. Africa / epidemiology. Asia / epidemiology. Carrier State. Child. Developing Countries. Disease Progression. Endemic Diseases. Female. Hepatitis B virus / immunology. Hepatitis B virus / pathogenicity. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / epidemiology. Humans. Immunization Schedule. Incidence. Infant, Newborn. Infectious Disease Transmission, Vertical / prevention & control. Male. Pregnancy. Pregnancy Complications, Infectious / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19896296.001).
  • [ISSN] 1768-3114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


9. Zhou XP, Yang GS, Lu JH, Zhang HB, Li QG, Han LZ, Zong M: [Prospective study of liver parenchyma volume in hepatectomy of primary liver cancer]. Zhonghua Wai Ke Za Zhi; 2005 Nov 1;43(21):1370-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective study of liver parenchyma volume in hepatectomy of primary liver cancer].
  • OBJECTIVE: To explore the secure resection margin (RM) of hepatectomy for primary liver cancer (PLC) with the coexistence of cirrhosis or hepatitis by studying the correlations of the resected liver parenchyma volume with postoperative liver function, complication and RM clinically.
  • METHODS: The volume of tumor and the surrounding liver in resected liver specimen was measured and calculated in continuous 76 PLC patients prospectively, and the total liver parenchyma volume was measured and calculated using computed tomography (CT) images in former 40 patients.
  • Under ideal circumstances, the surrounding liver volume, which would be resected theoretically, was calculated according to various sizes of tumors and RMs.
  • The correlations of the resected liver volume or hepatic parenchyma-resected rate (HPRR) with postoperative liver function, complication and RM were analysed.
  • The volume of the tumors and the surrounding liver in the specimens were (107 +/- 203) cm(3) and (153 +/- 120) cm(3), respectively.
  • In 40 patients, the total nontumorous liver volume using CT images was (1079 +/- 179) cm(3), and HPRR was (14 +/- 9)%.
  • The significant factors affecting liver function and complication are HPRR, the size of operation, the time of hepatic portal occlusion and the resected liver volume (P < 0.05) apart from preoperative liver function.
  • CONCLUSIONS: When hepatectomy was performed in PLC patients with preoperative liver function of Child A grade and the coexistence of cirrhosis or hepatitis, 30% HPRR was a lower limit for greatly increasing the chance of developing serious postoperative complications, while 20% HPRR was a safe upper limit for achieves quick postoperative recovery or developing only a few mild complications.
  • When PLC patients without macroscopic tumor thrombi or macrosatellites undergo hepatectomy, 10 mm RM is enough to ensure sufficient liver function residue and achieve complete micrometastasis clearance in liver parenchyma surrounding the lesion if the diameter of a tumor is less than 10 cm and 6 mm RM is enough to ensure sufficient liver function residue and obtain 99% micrometastasis clearance if the diameter of a tumor is greater than 10 cm, while with macroscopic tumor thrombi or macrosatellites, 20 mm RM is enough to ensure sufficient liver function residue and achieve 99% micrometastasis clearance if the diameter of a tumor is less than 6 cm.
  • [MeSH-major] Hepatectomy / methods. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatitis / complications. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Prospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318771.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


10. Coviello E, Caputi G, Martinelli D, Germinario CA, Prato R: Mortality trends for primary liver cancer in Puglia, Italy. Eur J Cancer Prev; 2010 Nov;19(6):417-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality trends for primary liver cancer in Puglia, Italy.
  • In the region of Puglia, Italy, the mortality rates from primary liver cancer (PLC) show a considerable geographical variability.
  • [MeSH-major] Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cities. Cohort Studies. Humans. Italy / epidemiology. Middle Aged. Mortality / trends. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647933.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Liu YM, Qin H, Wang CB, Fang XH, Ma QY: [Comparision of different interventional therapies for primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):232-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparision of different interventional therapies for primary liver cancer].
  • OBJECTIVE: To investigate the efficacy of different interventional therapies for primary hepatic cell cancer (HCC).
  • The results of liver function, alpha-fetoprotein, imaging, color-ultrasonography and survival rate were reviewed.
  • The Child grade of liver function, color-ultrasonography and alpha-fetoprotein of TACE + RFA group, TACE and TAI were compared.
  • CONCLUSION: Compared with other modalities, transcatheter arterial chemoembolization (TACE) before or after hepatectomy is more effective than other interventional therapies for primary hepatocellular cancer, whereas, if combined with radiofrequency ablation (TAI), it is much more effective than TACE alone.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649645.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


12. Chu KJ, Yao XP, Fu XH: Factors related to pleural effusion following hepatectomy for primary liver cancer. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):58-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to pleural effusion following hepatectomy for primary liver cancer.
  • BACKGROUND: Pleural effusion frequently complicates hepatectomy and multiple factors contribute to its development following hepatectomy for primary liver cancer.
  • METHODS: From March 2003 to May 2005, 228 consecutive patients with primary liver cancer underwent hepatectomy in our department were evaluated retrospectively to identify factors related to postoperative pleural effusion.
  • CONCLUSION: Subphrenic collection and operative injury to the liver appeared to be significantly related to pleural effusion after hepatectomy for primary liver cancer.
  • [MeSH-major] Hepatectomy / adverse effects. Liver Neoplasms / surgery. Pleural Effusion / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287168.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Li AJ, Zhou WP, Wu MC, Luo XJ: Hepatectomy after primary repair of ruptured liver cancer. Hepatobiliary Pancreat Dis Int; 2007 Jun;6(3):267-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatectomy after primary repair of ruptured liver cancer.
  • BACKGROUND: Spontaneous rupture of liver tumor is often considered a potentially life-threatening situation.
  • The aim of the present study was to assess re-operation after emergency repair of ruptured liver cancer.
  • METHODS: We reviewed retrospectively five patients who had been admitted within a one-year period and undergone a second operation after emergency repair of primary liver cancer rupture.
  • RESULTS: Five patients (4 males and 1 female) underwent emergency repair of ruptured liver cancer in local hospitals; three of them received transarterial chemoembolization (TACE).
  • CONCLUSIONS: Re-operation is indicated for patients with primary liver cancer rupture whose liver function is good and whose foci are localized and operable.
  • Apart from removing the primary foci, it is necessary to clear abdominal metastatic foci, irrigate the abdomen and administer chemotherapy to prolong the patient's life.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Reoperation. Rupture, Spontaneous

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548249.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Fléchon A, Rivoire M, Berger N: [Surgery of residual masses after chemotherapy in patients with testicular cancer]. Rev Prat; 2007 Feb 28;57(4):389-98
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of residual masses after chemotherapy in patients with testicular cancer].
  • [Transliterated title] Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule.
  • The primary site of metastases is the retroperitoneal lymph nodes.
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Controlled Clinical Trials as Topic. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Positron-Emission Tomography. Postoperative Complications. Prognosis. Prospective Studies. Radiotherapy Dosage. Retroperitoneal Space. Seminoma / drug therapy. Seminoma / radionuclide imaging. Seminoma / surgery. Teratoma / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455741.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 52
  •  go-up   go-down


15. Chen SG, Zhang SM, Zhao HT, Zhang N, Han K, Wang SB, Qu Q, Wei X, Rui J: [Results of multimodality therapy for unresectable primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):709-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of multimodality therapy for unresectable primary liver cancer].
  • OBJECTIVE: To investigate the therapeutic measures for unresectable primary liver cancer (PLC).
  • METHODS: The date of 312 unresectable primary liver cancer patients treated from January 1991 to March 2003 were retrospectively analyzed.
  • CONCLUSION: Treatment for the unresectable primary liver cancer should be individualized and combined with suitable therapeutic modalities.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Cryosurgery. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274382.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Xu J, Chen X: Expression of twist gene in primary liver cancer. J Huazhong Univ Sci Technolog Med Sci; 2007 Dec;27(6):668-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of twist gene in primary liver cancer.
  • In order to investigate the possibility of overexpression of Twist in primary liver cancer (PLC), the Twist expression was detected by using immunohistochemical analysis and RT-PCR assay in 45 patients with PLC.
  • Control tissues were obtained from 9 patients with liver hemangioma.
  • In noncancerous adjacent areas and control liver tissues, the expression of Twist was 57.8% and 22.2% respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Nuclear Proteins / genetics. Twist Transcription Factor / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231738.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Twist Transcription Factor
  •  go-up   go-down


17. Czeczot H, Skrzycki M, Podsiad M, Gawryszewska E, Nyckowski P, Porembska Z: [Antioxidant status of patients with primary colorectal cancer and liver metastases of colorectal cancer]. Pol Merkur Lekarski; 2005 Jan;18(103):58-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antioxidant status of patients with primary colorectal cancer and liver metastases of colorectal cancer].
  • In the present work we examined selected parameters of antioxidant status in patients with primary colorectal cancer and liver metastasis of colorectal cancer.
  • Total antioxidant status (TAS), activity of superoxide dismutase (SOD) and catalase (CAT) were examined in colorectal primary cancer, liver metastasis of colorectal cancer and in blood serum of patients before and after surgery.
  • [MeSH-major] Adenocarcinoma / metabolism. Antioxidants / metabolism. Catalase / metabolism. Colorectal Neoplasms / metabolism. Liver Neoplasms / metabolism. Superoxide Dismutase / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged


18. Wang Y, Chen KJ, Zhang YL, Sun YF, Wei GT, Hu L: [Extended hepatic pedicle occlusion in major hepatectomy for primary liver cancer]. Zhonghua Wai Ke Za Zhi; 2008 May 15;46(10):776-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extended hepatic pedicle occlusion in major hepatectomy for primary liver cancer].
  • OBJECTIVE: To evaluate the influence of extended hepatic pedicle occlusion (HPO) on hepatic ischemic/reperfusion (I/R) injury and intraoperative blood loss in major hepatectomy for primary liver cancer (PLC).
  • The amount of intraoperative blood loss, the percentage of the patients who needed blood transfusion and postoperative liver biochemical tests were compared between the two groups.
  • The two groups were matched for underlying liver disease ,preoperative liver function, tumor size and location, major intrahepatic vessel involvements and the types and extensions of the hepatectomies.
  • Patients in both of the groups were recovered smoothly after operation, with no occurrence of liver failure.
  • CONCLUSIONS: The hepatic pedicle can be continuously occluded for 3045 min in cirrhotic patients with well compensated liver function, and when compared to routine intermittent HPO, continuous HPO significantly decreases the intraoperative blood loss and reduces the need for transfusion.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / blood supply. Liver / physiopathology. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953936.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Huang YB, Lu BY, Cai XY, Liang ST, Huang F, Jin XJ: [Analysis of the effect of laparoscopic hepatectomy on 61 cases of primary liver cancer]. Zhonghua Wai Ke Za Zhi; 2008 Mar 15;46(6):411-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the effect of laparoscopic hepatectomy on 61 cases of primary liver cancer].
  • OBJECTIVE: To explore the feasibility and the effect of laparoscopic hepatectomy for primary liver cancer(PLC).
  • [MeSH-major] Hepatectomy / methods. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Feasibility Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785572.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


20. Liu MZ, Wang XS, Cai L, Gu MF, Liu H, Li Q, Cui NJ, Zhang YQ, Li GH, Li JQ: [External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer]. Ai Zheng; 2005 Jan;24(1):82-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer].
  • BACKGROUND & OBJECTIVE: Transcatheter arterial chemoembolization (TACE) is the routine treatment for unresectable primary liver cancer, but 3-year survival rate of patients received TACE alone is only about 20%.
  • This research was to evaluate efficacy of external radiotherapy (RT) combined with TACE on unresectable primary live cancer.
  • 2002, 114 patients with unresectable primary liver cancer were non-randomized to receive TACE plus RT (54 patients), or TACE alone (60 patients) as control.
  • Three-year survival rate correlated with tumor size, liver function grade, and portal vein embolus.
  • CONCLUSION: TACE combined with RT may prolong survival time of patients with unresectable primary live cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Particle Accelerators. Survival Rate. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642207.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; BG3F62OND5 / Carboplatin
  •  go-up   go-down


21. Shen XY, Chai CH, Xiao WB, Wang QD: Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):159-63
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of the fluoroscopic triggering 3D LAVA technique for primary liver cancer.
  • BACKGROUND: Primary liver cancer (PLC) is one of the common malignant tumors.
  • Liver acquisition with acceleration volume acquisition (LAVA), which allows simultaneous dynamic enhancement of the hepatic parenchyma and vasculature imaging, is of great help in the diagnosis of PLC.
  • This study aimed to evaluate application of the fluoroscopic triggering 3D LAVA technique in the imaging of PLC and liver vasculature.
  • RESULTS: Thirty-eight patients gave high quality images of 72 nodules in the liver for diagnosis.
  • [MeSH-major] Fluoroscopy / methods. Imaging, Three-Dimensional / methods. Liver / pathology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Hepatic Artery / pathology. Humans. Male. Middle Aged. Portal Vein / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382587.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Liang SX, Jiang GL, Zhu XD, Fu XL, Li FX, Huang QF, Wang AY, Chen L, Lu HJ: [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):613-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].
  • OBJECTIVE: To evaluate the toxicity and efficacy of primary liver cancer (PLC) treated by hypofractionated three-dimensional conformal radiotherapy (3DCRT) and investigate the prognostic factors.
  • 108 patients had Child-Pugh Grade A liver cirrhosis and 20 Child-Pugh Grade B liver cirrhosis.
  • CONCLUSION: T stage, GTV, PVTT and Child-Pugh Grade have significant impact on the overall survival in primary liver cancer patients treated by three-dimensional conformal radiotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438872.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M: Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol; 2006;45(7):838-47
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy of primary liver cancer and hepatic metastases.
  • The purpose was to evaluate the clinical results of stereotactic radiotherapy in primary liver tumors and hepatic metastases.
  • Five patients with primary liver cancer and 39 patients with 51 hepatic metastases were treated by stereotactic radiotherapy since 1997.
  • Median follow-up was 15 months (2-48 months) for primary liver cancer and 15 months (2-85 months) for hepatic metastases.
  • While all primary liver cancers were controlled, nine local failures (3-19 months) of 51 metastases were observed resulting in an actuarial local control rate of 92% after 12 months and 66% after 24 months and later.
  • Stereotactic irradiation of primary liver cancer and hepatic metastases offers a locally effective treatment without significant complications in patients, who are not amenable for surgery.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Radiotherapy Dosage. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982548.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


24. Wang YH, Liu JF, Li F, Li A, Liu Q, Liu DB, Liu DG, Wang YJ: Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver cancer. Chin Med J (Engl); 2009 Apr 20;122(8):889-94
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver cancer.
  • BACKGROUND: Radiofrequency ablation (RFA) followed by transarterial chemoembolization (TACE) for unresectable primary liver cancer (PLC) has not been widely discussed.
  • RFA response and liver function were significant variables influencing survival time as analyzed using the Cox regression model.
  • [MeSH-major] Catheter Ablation / methods. Chemoembolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493409.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Sun Z, Su YH, Yue XQ: [Professor Ling Changquan's experience in treating primary liver cancer: an analysis of herbal medication]. Zhong Xi Yi Jie He Xue Bao; 2008 Dec;6(12):1221-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Professor Ling Changquan's experience in treating primary liver cancer: an analysis of herbal medication].
  • On the basis of outpatients' medical records concerning primary liver cancer (PLC), data of 552 patients (with 2020 effective prescriptions) from the Outpatient Department of Changhai Hospital treated by Professor Ling Changquan were collected.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / drug therapy. Phytotherapy / methods
  • [MeSH-minor] Adult. Aged. Cluster Analysis. Female. Humans. Logistic Models. Male. Medicine, Chinese Traditional / methods. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19063833.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


26. Ocama P, Nambooze S, Opio CK, Shiels MS, Wabinga HR, Kirk GD: Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer; 2009 Mar 10;100(5):799-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005.
  • Primary liver cancer (PLC) incidence trends from Africa are unknown.
  • Using Kampala Cancer Registry data from 1960 to 1980 and 1991 to 2005, we identified 771 PLCs.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):1005-8 [17700568.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):147-52 [11246843.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1207-14 [11336472.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):290-6 [11668511.001]
  • [Cites] Nutrition. 2002 May;18(5):417-21 [11985948.001]
  • [Cites] East Afr Med J. 2002 Feb;79(2):68-72 [12380879.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1393-400 [14647050.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):460-8 [14762783.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Cancer. 1971 Jul;28(1):253-60 [4329335.001]
  • [Cites] East Afr Med J. 1972 Oct;49(10):783-90 [4666004.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1197-200 [192895.001]
  • [Cites] Hepatology. 1983 Jan-Feb;3(1):65-8 [6295908.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1990 Jan-Feb;84(1):144-7 [2189236.001]
  • [Cites] Lancet. 1991 Mar 2;337(8740):551 [1671909.001]
  • [Cites] IARC Sci Publ. 1991;(95):126-58 [1894318.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] Ann Acad Med Singapore. 1997 Sep;26(5):671-81 [9494677.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):56-63 [15654781.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1808-12 [15827554.001]
  • [Cites] J Hepatol. 2005 Jun;42(6):799-805 [15973779.001]
  • [Cites] Afr Health Sci. 2005 Jun;5(2):93-8 [16006214.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Aug;20(8):1185-90 [16048565.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1751-8 [16736026.001]
  • [Cites] Trop Med Int Health. 2006 Jun;11(6):951-4 [16772018.001]
  • [Cites] Int J Food Microbiol. 2006 Aug 1;110(3):217-23 [16822572.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2070-82 [16679307.001]
  • [Cites] Emerg Infect Dis. 2006 Sep;12(9):1440-3 [17073099.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1553-8 [17134360.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):492-7 [11170959.001]
  • (PMID = 19174820.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI042855; United States / NCI NIH HHS / CA / T32 CA009314; United States / NIAID NIH HHS / AI / P30AI42855
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653777
  •  go-up   go-down


27. Sun HW, Chen LH, Wei CJ, Zheng XK, Li QS, Guan J: [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jun;29(6):1133-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
  • OBJECTIVE: To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE).
  • Child-Pugh grade A of liver cirrhosis was present in 64 cases and grade B in 20 cases.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Hepatocellular / therapy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / hydroxycamptothecinum; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


28. Zhang XF, Bian JC, Zhang XY, Zhang ZM, Jiang F, Wang QM, Wang QJ, Cao YY, Tang BM: Are polymorphisms of N-acetyltransferase genes susceptible to primary liver cancer in Luoyang, China? World J Gastroenterol; 2005 Mar 14;11(10):1457-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are polymorphisms of N-acetyltransferase genes susceptible to primary liver cancer in Luoyang, China?
  • AIM: To identify whether the polymorphisms of the N-acetyltransferase (NAT) genes are susceptible to primary liver cancer (PLC) in Luoyang, a PLC low-incidence area of China.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Genetic Predisposition to Disease. Liver Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China. Female. Humans. Isoenzymes. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770721.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  • [Other-IDs] NLM/ PMC4305687
  •  go-up   go-down


29. Wu MC: [Progress in diagnosis and treatment of primary liver cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug;30(4):363-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress in diagnosis and treatment of primary liver cancer].
  • The early diagnosis, surgical treatment, and comprehensive treatment of primary liver cancer (PLC) have advanced greatly in recent years.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Early Diagnosis. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795602.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Bruin SC, Klijn C, Liefers GJ, Braaf LM, Joosse SA, van Beers EH, Verwaal VJ, Morreau H, Wessels LF, van Velthuysen ML, Tollenaar RA, Van't Veer LJ: Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer; 2010;10:662
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.
  • BACKGROUND: Accurate staging of colorectal cancer (CRC) with clinicopathological parameters is important for predicting prognosis and guiding treatment but provides no information about organ site of metastases.
  • Patterns of genomic aberrations in primary colorectal tumors may reveal a chromosomal signature for organ specific metastases.
  • METHODS: Array Comparative Genomic Hybridization (aCGH) was employed to asses DNA copy number changes in primary colorectal tumors of three distinctive patient groups.
  • This included formalin-fixed, paraffin-embedded tissue of patients who developed liver metastases (LM; n = 36), metastases (PM; n = 37) and a group that remained metastases-free (M0; n = 25).A novel statistical method for identifying recurrent copy number changes, KC-SMART, was used to find specific locations of genomic aberrations specific for various groups.
  • RESULTS: Specifically in the tumors of primary CRC patients who subsequently developed liver metastasis, KC-SMART analysis identified genomic aberrations on chromosome 20q.
  • LM-PAM, a shrunken centroids classifier for liver metastases occurrence, was able to distinguish the LM group from the other groups (M0&PM) with 80% accuracy (78% sensitivity and 86% specificity).
  • CONCLUSION: Liver specific CRC metastases may be predicted with a high accuracy based on specific genomic aberrations in the primary CRC tumor.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 20. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Gene Dosage. Liver Neoplasms / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Comparative Genomic Hybridization. Databases, Genetic. Female. Fixatives. Formaldehyde. Gene Expression Profiling / methods. Genetic Predisposition to Disease. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Netherlands. Oligonucleotide Array Sequence Analysis. Paraffin Embedding. Phenotype. Predictive Value of Tests. Survival Analysis. Time Factors. Tissue Fixation / methods. Treatment Outcome


31. Kasem AR, Desai A, Daniell S, Sinha P: Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer. Breast J; 2006 Nov-Dec;12(6):544-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer.
  • The aim of the present study was to investigate the value of preoperative staging in primary operable breast cancer.
  • This retrospective study included patients presenting between May 1999 and February 2004 with operable primary breast cancer.
  • Of the 189 patients with normal BS 182 had normal liver ultrasound (US), whereas the remaining seven patients underwent computed tomography scan which was normal in five and two confirmed liver metastases (one with abnormal LFTs).
  • BS and liver US truly altered treatment in 3% of patients.
  • Preoperative staging with liver US and BS should be reserved for high-risk patients.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Breast Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone and Bones / radionuclide imaging. Female. Humans. Liver / ultrasonography. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity


32. Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, Yasuno M, Sugihara K: Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol; 2007 Sep;37(9):679-85
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer.
  • BACKGROUND: Angiogenesis is required for growth and metastasis of colorectal cancer (CRC), and several positive regulators of tumor angiogenesis have been identified.
  • Cyclooxygenase-2 (COX-2), known to be elevated in several human cancers, regulates angiogenesis by inducing angiogenic factors.
  • The aim of this study was to clarify the levels and evaluate the relationships of COX-2, vascular endothelial growth factor A and C, thymidine phosphorylase (TP) and microvascular density (MVD) in paired tissue specimens between primary CRC and corresponding metastatic liver cancer.
  • METHODS: Tissue samples from pairs of primary tumors and corresponding metastatic liver tumors from 44 patients with CRC were immunohistochemically evaluated for COX-2, VEGF-A, VEGF-C, TP and MVD.
  • RESULTS: The primary and corresponding metastatic liver tumors tended to show concordant immunoreactivity for COX-2 (P = 0.005, rs = 0.428), VEGF-A (P = 0.039, rs = 0.314), TP (P = 0.005, rs = 0.422) and MVD (P = 0.046, rs = 0.304) by Spearman rank test.
  • The rate of COX-2 immunoreactivity was higher in liver metastases than in primary tumors (P = 0.002), while the rate of VEGF-A was higher in primary tumors than in liver metastases (P = 0.0004).
  • The incidence of TP immunoreactivity and the level of MVD did not differ between primary and metastatic liver tumors (P = 0.247; P = 0.229).
  • Significant correlations were found between COX-2 immunoreactivity and VEGF-A immunoreactivity in metastatic liver tumors (P = 0.033) as well as in primary tumors (P = 0.008).
  • CONCLUSION: The positive correlations between COX-2, VEGF-A, TP and MVD in primary CRC and liver metastasis as demonstrated here will help to predict the angiogenic activity of liver metastasis by analyzing primary tumors, allowing for individualized cancer treatment options.
  • [MeSH-major] Angiogenesis Inducing Agents / analysis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Cyclooxygenase 2 / analysis. Liver Neoplasms / blood supply. Liver Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microcirculation. Middle Aged. Thymidine Phosphorylase / analysis. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor C / analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846040.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


33. Fang CH, Lu CM, Huang YP, Li XF, Fan YF, Yang J, Xiang N, Pan JH: [Study on the application of value of digital medical technology in the operation on primary liver cancer]. Zhonghua Wai Ke Za Zhi; 2009 Apr 1;47(7):523-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the application of value of digital medical technology in the operation on primary liver cancer].
  • OBJECTIVE: To study the clinical application of digital medical in the operation on primary liver cancer.
  • METHODS: The patients (n=11) with primary hepatic carcinoma treated between February and July 2008, including 9 cases of hepatocellular carcinoma, 2 cases of cholangiocellular carcinoma, were scanned using 64 slices helicon computerized tomography (CT) and the datasets was collected.
  • RESULTS: The reconstructed models were true to life, and their spatial disposition and correlation were shown clearly; Blood supply of primary liver cancer could be seen easily.
  • CONCLUSIONS: Digital medical benefited knowing the relationship between primary liver cancer and the intrahepatic pipe.
  • It gave an advantage to complete primary liver cancer resection with more liver volume remained.
  • [MeSH-major] Computer Simulation. Liver Neoplasms / surgery. User-Computer Interface
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Liver / radiography. Liver / surgery. Male. Middle Aged. Models, Anatomic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595211.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


34. Huh JW, Cho CK, Kim HR, Kim YJ: Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases. J Gastrointest Surg; 2010 Aug;14(8):1258-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases.
  • PURPOSE: This study was designed to evaluate the impact of resection for primary colorectal cancer on oncologic outcomes in patients with synchronous colorectal liver metastases.
  • METHODS: A retrospective analysis was performed on 91 consecutive patients with synchronous colorectal liver metastases who underwent resection of the primary colorectal cancer between December 1999 and December 2007.
  • Of the 91 patients, 54 (59.3%) also underwent complete (R0) resection for liver metastases, and 84 (92.3%) received postoperative chemotherapy.
  • A multivariate analysis revealed that residual disease after surgery (non-R0 resection; p = 0.003), lymph node metastasis of the primary tumor (p = 0.015), and no postoperative chemotherapy (p = 0.001) were independent prognostic factors for poor survival.
  • Independent predictors of an inability to achieve a complete resection were the presence of three or more liver metastases and the presence of extrahepatic disease at exploration.
  • CONCLUSIONS: The inability to safely render the liver and colon microscopically free of disease should cause a surgeon to reconsider synchronous colectomy and hepatectomy.
  • A multidisciplinary approach that combines both complete resection of synchronous colorectal liver metastases and postoperative chemotherapy may achieve improved survival in patients with synchronous colorectal liver metastases.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Hepatectomy / methods. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Portography. Positron-Emission Tomography. Republic of Korea / epidemiology. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544397.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


36. Qu CX, Kamangar F, Fan JH, Yu B, Sun XD, Taylor PR, Chen BE, Abnet CC, Qiao YL, Mark SD, Dawsey SM: Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China. J Natl Cancer Inst; 2007 Aug 15;99(16):1240-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China.
  • BACKGROUND: Primary liver cancer is a common malignancy with a dismal prognosis.
  • New primary prevention strategies are needed to reduce mortality from this disease.
  • We examined the effects of supplementation with four different combinations of vitamins and minerals on primary liver cancer mortality among 29450 initially healthy adults from Linxian, China.
  • The study outcome was primary liver cancer death occurring from 1986 through 2001.
  • Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of liver cancer death with and without each factor.
  • RESULTS: A total of 151 liver cancer deaths occurred during the analysis period.
  • No statistically significant differences in liver cancer mortality were found comparing the presence and absence of any of the four intervention factors.
  • However, both factor A and factor B reduced liver cancer mortality in individuals younger than 55 years at randomization (HR = 0.59, 95% CI = 0.34 to 1.00, and HR = 0.54, 95% CI = 0.31 to 0.93, respectively) but not in older individuals (HR = 1.06, 95% CI = 0.71 to 1.59, and HR = 1.12, 95% CI = 0.75 to 1.68, respectively).
  • Factor C reduced liver cancer death, albeit with only borderline statistical significance in males (HR = 0.70, 95% CI = 0.47 to 1.02) but not in females (HR = 1.30, 95% CI = 0.72 to 2.37).
  • Cumulative risks of liver cancer death were 6.0 per 1000 in the placebo arm, 5.4 per 1000 in the arms with two factors, and 2.4 per 1000 in the arm with all four factors.
  • CONCLUSION: None of the factors tested reduced overall liver cancer mortality.
  • However, three factors reduced liver cancer mortality in certain subgroups.
  • [MeSH-major] Liver Neoplasms / mortality. Liver Neoplasms / prevention & control. Minerals / therapeutic use. Vitamins / therapeutic use
  • [MeSH-minor] Adult. Antibodies, Neoplasm / blood. Chemoprevention. China. Double-Blind Method. Drug Therapy, Combination. Female. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Minerals.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686823.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / CCR NIH HHS / RC / N01-RC-47701; United States / NCI NIH HHS / SC / N01-SC-91030; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Minerals; 0 / Vitamins
  •  go-up   go-down


37. Yue XQ, Gao JD, Zhai XF, Liu Q, Jiang D, Ling CQ: [Correlation between the width of lingual vein and the changes of hemodynamics of portal system in patients with primary liver cancer]. Zhong Xi Yi Jie He Xue Bao; 2006 Sep;4(5):482-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between the width of lingual vein and the changes of hemodynamics of portal system in patients with primary liver cancer].
  • OBJECTIVE: To explore the correlation between the width of lingual varix and changes of hemodynamics of portal system in patients with primary liver cancer so as to supply the data for the forecast of portal hypertension by observing lingual varix.
  • CONCLUSION: The width of lingual vein is closely correlated with the diameters of portal vein and splenic vein in patients with primary liver cancer.
  • [MeSH-major] Hemodynamics. Hypertension, Portal / physiopathology. Liver Neoplasms / physiopathology. Tongue / blood supply. Veins / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / physiopathology. Female. Humans. Male. Medicine, Chinese Traditional. Middle Aged. Portal Vein / physiopathology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965741.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


38. Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, Abe H, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M: KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):960-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.
  • This study aimed to assess subcellular localization of KL-6 mucin in liver metastatic tissues from colorectal carcinoma and hepatocellular carcinoma tissues.
  • METHODOLOGY: Tissue samples were collected from 56 patients with liver metastasis of colorectal carcinoma and 92 patients with hepatocellular carcinoma who underwent a hepatectomy.
  • RESULTS: All 56 cases with metastatic liver cancer showed positive staining for KL-6 mucin in cancer tissues but not in non-cancerous tissues.
  • All staining was observed in the circumferential membrane and/or cytoplasm of the cancer cells.
  • CONCLUSIONS: KL-6 mucin may be an indicator for liver metastasis of colorectal carcinoma.
  • Additionally, detection of KL-6 mucin may be helpful in distinguishing hepatocellular carcinoma from metastatic liver cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Hepatocellular / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged


39. Guan CN, Cai LZ, Yue LQ, Zhang Y: [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy]. Zhongguo Zhong Yao Za Zhi; 2006 Mar;31(6):510-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy].
  • OBJECTIVE: To study the effects of Yanshu injection on the combined treatment in the advanced primary liver cancer.
  • METHOD: Eighty-five cases of advanced primary liver cancer were treated with Yanshu injection combining with chemotherapy or only chemotherapy.
  • CONCLUSION: Yanshu injection combination with chemotherapy can raise the curative effect, one year survival rate and cellular immune function, reduce pain genesic rate and toxicity of chemotherapy, and improve the quality of life of the patients with advanced primary liver cancer, which is worthy to be recommended for clinical application.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / drug therapy. Phytotherapy. Sophora
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Plants, Medicinal / chemistry. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722388.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


40. Wu D, Bao WG, Ding YH: [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec;25(12):1066-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites].
  • OBJECTIVE: To observe the clinical efficacy of Xiaoshui Decoction (XSD) in treating ascites in patients suffered from primary liver cancer of Pi-deficiency with damp harassment syndrome (PDDHS) as well as to study the effect through the experiment in mice.
  • METHODS: Sixty-one patients confirmed to be primary liver cancer of PDDHS and accompanied with ascites were randomly divided into the treated group (n=33) and the control group (n=28).
  • CONCLUSION: Satisfactory short-term efficacy in treating primary liver cancer with ascites of the Pi-deficiency with damp harassment syndrome could be obtained by XSD.
  • XSD can also improve the symptoms and QOL of patients, therefore, it is an effective and reliable remedy for treatment of primary liver cancer with ascites.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398423.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


41. Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, Bruch HP: Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg; 2006 Apr;391(2):118-23
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients.
  • BACKGROUND AND AIMS: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors.
  • PATIENTS AND METHODS: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients.
  • Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%).
  • Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound.
  • CONCLUSION: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604376.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Wang WH, Zhou RY, Yan ZP: [Regulatory effect of bushen jianpi recipe on cellular immunity of patients with primary liver cancer after intervention therapy]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Jul;28(7):583-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regulatory effect of bushen jianpi recipe on cellular immunity of patients with primary liver cancer after intervention therapy].
  • OBJECTIVE: To observe the regulatory effect of Bushen Jianpi Recipe (BSJPR) on cellular immunity the of primary liver cancer patients of Gan-Shen yin-deficiency and Pi qi-deficiency syndrome type after intervention therapy.
  • METHODS: According to the multi-center randomized controlled principle, 117 patients after transcatheter arterial chemoembolization (TACE) were assigned to two groups, 60 in the treated group and 57 in the control group, who were treated respectively with BSJPR and liver protecting remedy (silymarin and vitamin c) for 12 weeks.
  • CONCLUSION: Using BSJPR together with TACE could enhance patients' cellular immune function to elevate the clinical curative effect on primary liver cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822903.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Silymarin; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


43. Dal Maso L, Lise M, Zambon P, Crocetti E, Serraino D, Ricceri F, Vercelli M, De Lisi V, Tagliabue G, Federico M, Falcini F, Cassetti T, Donato A, Fusco M, Budroni M, Ferretti S, Tumino R, Piffer S, Bellù F, Mangone L, Giacomin A, Vitarelli S, Franceschi S: Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysis. Eur J Cancer; 2008 Jan;44(2):285-92
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysis.
  • We conducted in Italy a study to evaluate trends of primary liver cancer (PLC) and to disentangle the period from birth-cohort effects on PLC incidence.
  • Cases aged<80 years and diagnosed between 1988 and 2002 in 20 areas covered by population-based Cancer Registries were included.
  • [MeSH-major] Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Incidence. Italy / epidemiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155898.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Lu PX, Wang JB, Zhang QN, Wu Y, Sun Y, Chen TY: [Longitudinal study of aflatoxin exposure in the development of primary liver cancer in patients with chronic hepatitis]. Zhonghua Yi Xue Za Zhi; 2010 Jun 22;90(24):1665-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Longitudinal study of aflatoxin exposure in the development of primary liver cancer in patients with chronic hepatitis].
  • OBJECTIVE: To study the relationship between aflatoxin exposure and the development of primary liver cancer (PLC) in patients with chronic hepatitis.
  • The urine excretion of AFM1 was also obviously related with the abnormal liver function (P = 0.035).
  • 96/100 000) significantly higher than that of cohort people (P = 0.001) and the same natural peoples (P = 0.000, RR = 15.09). (6) It took an average time of 14.65 years (median 13.68) from hepatitis occurrence to PLC diagnosis and 7.38 years (median 6.40) from liver cirrhosis to PLC diagnosis.
  • [MeSH-major] Aflatoxins / adverse effects. Environmental Exposure. Hepatitis B, Chronic / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Carrier State. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979873.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aflatoxins
  •  go-up   go-down


45. Neff R, Abdel-Misih R, Khatri J, Dignazio M, Garcia M, Petrelli N, Wilson P: The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest; 2008 Mar;26(2):173-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
  • The yttrium-90 radiation dose was dependent upon the percentage of tumor involvement of the liver, with a dose modification (reduction) adjusted for macroaggregated albumin (MAA) shunted to the lung.
  • RESULTS: Twenty-one patients underwent twenty-five treatments with SIR microsphere therapy for primary and metastatic liver tumors.
  • CONCLUSIONS: The application of SIR microspheres has been utilized for a variety of liver tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiotherapy. Female. Hepatic Artery / radiation effects. Humans. Male. Microspheres. Middle Aged. Neoplasm, Residual / radiotherapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiotherapy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259948.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


46. Yan JJ, Zhang XH, Chu KJ, Huang L, Zhou FG, Yan YQ: Prevention and management of pleural effusion following hepatectomy in primary liver cancer. Hepatobiliary Pancreat Dis Int; 2005 Aug;4(3):375-8
Hazardous Substances Data Bank. Argon, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention and management of pleural effusion following hepatectomy in primary liver cancer.
  • The risk factors, prevention and management of postoperative pleural effusion in patients with primary liver cancer (PLC) who have undergone hepatectomy and the value of the argon beam coagulator (ABC) for the prevention of pleural effusion are studied.
  • CONCLUSIONS: Dissociation of the liver by argon beam cutting and/or coagulation can save suture ligation of the diaphragmatic secondary wound surface and may also prevent postoperative pleural effusion.
  • [MeSH-major] Hepatectomy / adverse effects. Laser Coagulation. Liver Neoplasms / surgery. Pleural Effusion / prevention & control. Pleural Effusion / therapy
  • [MeSH-minor] Adult. Aged. Argon. Catheterization, Central Venous. Drainage. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109519.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  •  go-up   go-down


47. Clemente G, De Rose AM, Giordano M, Mele C, Vellone M, Ardito F, Murazio M, Giuliante F, Giovannini I, Nuzzo G: [Primary intrahepatic lithiasis: indications and results of liver resection]. Chir Ital; 2009 May-Jun;61(3):273-80
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intrahepatic lithiasis: indications and results of liver resection].
  • The aim of this study was to review a series of patients submitted to hepatectomy for primary intrahepatic lithiasis to evaluate early and late results with an assessment of indications, methods and long-term outcomes.
  • From January 1992 to December 2007, 40 patients (25 males and 15 females with a mean age of 51 years) underwent surgery for primary intrahepatic lithiasis in our Hepato-biliary Surgery Unit.
  • A cholangiocarcinoma was found in 4 patients (10%) and only two of these underwent liver resection, while an exploratory laparotomy was performed in the remaining two patients for an unresectable tumour, unexpected before surgery.
  • Primary intrahepatic lithiasis is diagnosed increasingly in Western countries as a result of the improvement in imaging techniques.
  • The stones originate inside the liver at the level of dilatations of the bile ducts above congenital strictures of the main hilar ducts.
  • In the majority of cases, a single liver lobe or segment is involved and liver resection allows definitive treatment of the disease and prevention of cancer.
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Cholestasis, Intrahepatic / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694228.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Li DT, Ling CQ, Zhu DZ: [Study on the quantitative evaluation on the degree of TCM basic syndromes often encountered in patients with primary liver cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul;27(7):602-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the quantitative evaluation on the degree of TCM basic syndromes often encountered in patients with primary liver cancer].
  • OBJECTIVE: To establish a quantitative model for evaluating the degree of the TCM basic syndromes often encountered in patients with primary liver cancer (PLC).

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717917.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


49. Lin HT, Liu GJ, Wu D, Lou JY: Metastasis of primary gallbladder carcinoma in lymph node and liver. World J Gastroenterol; 2005 Feb 7;11(5):748-51
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of primary gallbladder carcinoma in lymph node and liver.
  • AIM: To evaluate the patterns with metastasis of gallbladder carcinoma in lymph nodes and liver.
  • The patterns with metastasis of primary gallbladder carcinoma in lymph nodes and liver were examined histopathologically and classified as TNM staging of the American Joint Committee on Cancer.
  • RESULTS: Of the 45 patients, 29 (64.4%) had a lymph node positive disease and 20 (44.4%) had a direct invasion of the liver.
  • The frequency of involvement of lymph nodes was strongly influenced by the depth of the primary tumor (P = 0.0001).
  • CONCLUSION: Complete resection of the regional lymph nodes is important in advanced primary gallbladder carcinoma (PGC).
  • The initial sites of liver spread are located mostly in segments IV and V.
  • [MeSH-major] Gallbladder Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholecystectomy. Hepatectomy. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655837.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250754
  •  go-up   go-down


50. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M: S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology; 2007 Dec;54(80):2315-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
  • BACKGROUND/AIMS: 5-FU plus Cisplatin combination therapy had been employed against primary liver carcinomas for years.
  • S-1 is a fourth-generation oral fluoropyrimidine and attracts considerable interest for the activity against gastric cancer.
  • We herein examined the effect and adverse effects of S-1 plus Cisplatin combination therapy for primary liver carcinomas.
  • They all had far-advanced diseases in and/or out of the liver at the time of the therapy initiation.
  • CONCLUSIONS: S-1 plus Cisplatin combination therapy is a potential therapy for advanced primary liver carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265655.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


51. Ishibashi K, Sobajima J, Ishiguro T, Okada N, Miyazaki T, Yokoyama M, Ishida H: [Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue]. Gan To Kagaku Ryoho; 2009 Mar;36(3):425-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of thymidine phosphorylase in primary colorectal cancer and liver metastasis-relationship between mRNA levels in cancer cells and protein levels in cancerous tissue].
  • PURPOSE: To compare mRNA levels in cancer cells and protein levels in cancerous tissue in terms of the expression of thymidine phosphorylase(TP).
  • MATERIALS AND METHODS: The materials were resected specimens of primary colorectal cancer(n=84)and synchronous liver metastasis(n=15).
  • The expressions of TP mRNA in cancer cells was quantified by reverse-transcriptase polymerase chain reaction(RT-PCR)using cells obtained by microdissection of paraffinembedded specimens(Danenberg tumor profiling method).
  • RESULTS: There was a weak relationship between TP mRNA levels and TP protein levels in primary colorectal cancers(p=0.04), but these factors did not correlate with each other in liver metastases.
  • There was no relationship between primary colorectal lesions and synchronous liver metastases in terms of TP mRNA levels and TP protein levels.
  • In relation to the efficacy of 5-fluorouracil(or UFT)/Leucovorin, the mRNA level of the primary lesion was marginally higher in the order of patients with PD(n=11), SD(n=3), and CR/PR(n=4)(p=0.05).
  • CONCLUSIONS: The different methods of determining the expression of TP in colorectal cancer specimens do not correlate with each other and may cause different therapeutic results after 5-fluorouracil-based chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / enzymology. Colorectal Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Liver Neoplasms / enzymology. Liver Neoplasms / secondary. Thymidine Phosphorylase / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295266.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


52. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA: Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer; 2007;7:118
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
  • The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated.
  • This study aims to examine associations between common CYP3A4 and CYP3A5 polymorphisms and digestive cancer risk.
  • METHODS: CYP3A4 and CYP3A5 genotypes were determined in 574 individuals including 178 patients with primary liver cancer, 82 patients with gastric cancer, 151 patients with colorectal cancer, and 163 healthy individuals.
  • RESULTS: The variant allele frequencies for patients with liver cancer, gastric cancer, colorectal cancer and healthy controls, respectively, were: CYP3A4*1B, 4.8 % (95% C.I.
  • CONCLUSION: Common polymorphisms on CYP3A4 and CYP3A5 genes do not modify the risk of developing digestive cancers in Western Europe.
  • [MeSH-major] Colorectal Neoplasms / genetics. Cytochrome P-450 Enzyme System / genetics. Genetic Variation. Liver Neoplasms / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Chi-Square Distribution. Cytochrome P-450 CYP3A. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymorphism, Genetic. Reference Values. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):519-22 [10769717.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):825-41 [15496535.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):209-14 [11181440.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):348-51 [11159790.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):631-5 [11422615.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1259-66 [11751443.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Clin Pharmacol Ther. 2002 Mar;71(3):196-204 [11907494.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(5):385-92 [12210502.001]
  • [Cites] Drug Metab Rev. 2002 Aug;34(3):667-76 [12214673.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):681-6 [12237780.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1668-71 [12324482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1019-24 [12376502.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1839-49 [12419832.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1897-901 [12419838.001]
  • [Cites] Hum Hered. 2002;54(1):13-21 [12446983.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:447-52 [12505350.001]
  • [Cites] Br J Clin Pharmacol. 2003 Jan;55(1):68-76 [12534642.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:149-73 [12171978.001]
  • [Cites] J Pharm Pharmacol. 2003 Jan;55(1):59-66 [12625868.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):527-34 [12813131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):928-32 [14504207.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):595-606 [14515058.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):607-18 [14515059.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1257-63 [14535982.001]
  • [Cites] Pharmacogenomics. 2004 Apr;5(3):243-72 [15102541.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Clin Pharmacol Ther. 2004 Aug;76(2):99-103 [15289786.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):842-52 [15496536.001]
  • [Cites] Hum Genet. 1986 Aug;73(4):320-6 [3017841.001]
  • [Cites] Carcinogenesis. 1991 Feb;12(2):355-9 [1899812.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):101-8 [8261428.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 [8035341.001]
  • [Cites] Carcinogenesis. 1994 Dec;15(12):2715-20 [8001226.001]
  • [Cites] Pharmacogenetics. 1994 Oct;4(5):247-59 [7894497.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2167-70 [7554070.001]
  • [Cites] Age Ageing. 1997 Mar;26(2):147-51 [9177672.001]
  • [Cites] Mutat Res. 1997 May 12;376(1-2):153-60 [9202751.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1623-30 [9276639.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1225-9 [9719084.001]
  • [Cites] Environ Health Perspect. 1994 Oct;102(10):852-3 [9644192.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8461-7 [15548719.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):331-5 [15637738.001]
  • [Cites] J Cell Biochem. 2005 Apr 1;94(5):917-43 [15578590.001]
  • [Cites] World J Gastroenterol. 2005 Mar 28;11(12):1867-71 [15793883.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1077-83 [15801491.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):275-82 [15978331.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5552-9 [16110016.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):299-305 [16171783.001]
  • [Cites] BMC Clin Pharmacol. 2005;5:4 [16253141.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):259-64 [15352038.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1087-91 [11099063.001]
  • (PMID = 17605821.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Other-IDs] NLM/ PMC1931602
  •  go-up   go-down


53. Faraj W, Mukherji D, El Majzoub N, Shamseddine A, Shamseddine A, Khalife M: Primary undifferentiated embryonal sarcoma of the liver mistaken for hydatid disease. World J Surg Oncol; 2010;8:58
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary undifferentiated embryonal sarcoma of the liver mistaken for hydatid disease.
  • Primary undifferentiated embryonal sarcoma of the liver is a rare tumor with a peak incidence between the ages of 6 and 10 years.
  • We report a case of a primary hepatic undifferentiated embryonal sarcoma arising in a 21-year-old male mistaken for hydatid disease of the liver.
  • [MeSH-major] Echinococcosis, Hepatic / diagnosis. Liver Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):136-40 [10657876.001]
  • [Cites] J Pediatr Surg. 2009 Dec;44(12):e1-3 [20005995.001]
  • [Cites] Cancer. 1978 Jul;42(1):336-48 [208754.001]
  • [Cites] Ann Clin Lab Sci. 1994 Nov-Dec;24(6):495-500 [7847778.001]
  • [Cites] Br J Radiol. 1997 Mar;70:314-6 [9166061.001]
  • [Cites] Radiology. 1997 Jun;203(3):779-83 [9169704.001]
  • [Cites] Surg Today. 2004;34(12):987-96 [15580379.001]
  • [Cites] Am J Transplant. 2006 Feb;6(2):392-7 [16426326.001]
  • [Cites] Chir Ital. 2007 Sep-Oct;59(5):611-25 [18019633.001]
  • [Cites] Rev Esp Enferm Dig. 2008 Feb;100(2):82-5 [18366265.001]
  • [Cites] Cancer. 2008 May 15;112(10):2274-82 [18361435.001]
  • [Cites] J Pediatr Surg. 2008 Jun;43(6):E1-4 [18558156.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(5):536-44 [18836810.001]
  • [Cites] J Pediatr Surg. 2009 Feb;44(2):e33-8 [19231519.001]
  • [Cites] Arch Surg. 2009 Apr;144(4):339-44; discussion 344 [19380647.001]
  • [Cites] Trop Gastroenterol. 2001 Jul-Sep;22(3):141-2 [11681107.001]
  • (PMID = 20615265.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2913916
  •  go-up   go-down


54. Shah AJ, Callaway M, Thomas MG, Finch-Jones MD: Contrast-enhanced intraoperative ultrasound improves detection of liver metastases during surgery for primary colorectal cancer. HPB (Oxford); 2010 Apr;12(3):181-7
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced intraoperative ultrasound improves detection of liver metastases during surgery for primary colorectal cancer.
  • BACKGROUND: Computed tomography (CT) is the most common staging investigation in colorectal cancer (CRC).
  • Up to 25% of patients are found to have previously undetected hepatic lesions when intraoperative ultrasound (IOUS) of the liver is used during CRC resection.
  • We aimed to assess the ability of IOUS to detect additional liver lesions/metastases at primary colorectal resection, and to evaluate whether contrast-enhanced IOUS (CE-IOUS) improves the detection and characterization of hepatic lesions.
  • At CRC resection, patients underwent IOUS of the liver.
  • Contrast-enhanced IOUS of the liver was undertaken using i.v. sulphur hexafluoride micro-bubbles (SonoVue, 4.8 ml).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged, 80 and over. Contrast Media. Female. Humans. Intraoperative Care. Male. Middle Aged. Pilot Projects. Prospective Studies. Sulfur Hexafluoride

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] J Clin Ultrasound. 2008 Jan;36(1):20-6 [17937421.001]
  • [Cites] Eur J Ultrasound. 2003 Feb;16(3):211-6 [12573790.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):454-8; discussion 458-9 [12682536.001]
  • [Cites] Radiology. 2003 May;227(2):361-70 [12649417.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1233-40 [15100125.001]
  • [Cites] Eur J Surg Oncol. 2004 Oct;30(8):834-41 [15336728.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1165-7 [15449268.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1361-9 [15376205.001]
  • [Cites] J Pathol. 1986 Nov;150(3):195-203 [3806280.001]
  • [Cites] Ann Surg. 1989 Aug;210(2):127-38 [2667471.001]
  • [Cites] Liver Int. 2008 Jan;28(1):88-94 [17971094.001]
  • [Cites] World J Gastroenterol. 2008 May 28;14(20):3207-11 [18506927.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):45-8 [1998863.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Surg Oncol. 1997;6(1):19-30 [9364658.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] J Ultrasound Med. 2004 Dec;23(12):1549-55 [15557298.001]
  • [Cites] J Ultrasound Med. 2004 Dec;23(12):1557-68 [15557299.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dig Dis Sci. 2005 Mar;50(3):533-7 [15810637.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1165-8 [15997444.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):236-40 [16432357.001]
  • [Cites] Colorectal Dis. 2006 Mar;8(3):192-4 [16466558.001]
  • [Cites] World J Gastroenterol. 2006 Mar 21;12(11):1699-705 [16586537.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):818-26 [17136470.001]
  • [Cites] World J Surg. 2002 May;26(5):550-4 [12098044.001]
  • (PMID = 20590885.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; WS7LR3I1D6 / Sulfur Hexafluoride
  • [Other-IDs] NLM/ PMC2889270
  •  go-up   go-down


55. Deng WZ, Yue XQ, Liu Q, Gao JD, Ren RZ, Ling CQ: [Comparative study on normal tongue manifestation in patients with primary liver cancer and healthy adults]. Zhong Xi Yi Jie He Xue Bao; 2006 Jan;4(1):13-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study on normal tongue manifestation in patients with primary liver cancer and healthy adults].
  • OBJECTIVE: To find out some microscopically visible morphological differences in normal tongue manifestation between patients with primary liver cancer and healthy adults, and provide some beneficial evidences for microcosmic syndrome differentiation of tongue inspection.
  • METHODS: Microcirculations of the tongue tip, which represented the macroscopical normal tongue manifestation, were observed under an optical microscope in patients with primary liver cancer and healthy adults.
  • RESULTS: The proportion of normal tongue manifestation was larger in healthy adults (38.89%) than that in patients with primary liver cancer (2.32%).
  • The total score of microcirculation of tongue tip and the maturation index of exfoliated cells from tongue coating were both higher in patients with primary liver cancer than those in healthy adults with normal tongue manifestation (P<0.01, P<0.05).
  • CONCLUSION: Normal tongue manifestation, which is macroscopically visible, can be observed in both patients with primary liver cancer and healthy adults, but there exists obvious difference in microcosmic view.
  • [MeSH-major] Liver Neoplasms / diagnosis. Medicine, Chinese Traditional. Tongue / anatomy & histology. Tongue / pathology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409961.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


56. Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B: [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Rev Pneumol Clin; 2010 Oct;66(5):313-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
  • [Transliterated title] Impact de la tomographie par émission de positons au 18-FDG dans la prise en charge des patients porteurs d'un cancer bronchique non à petites cellules a priori opérable. Etude prospective multicentrique française.
  • BACKGROUND: Whole-body (18)F-deoxyglucose positron emission tomography (FDG-PET) has the potential to improve the management of non-small-cell lung cancer (NSCLC).
  • These modifications were retrospectively justified in 9/19 cases, and consisted of 2/4 modifications of the surgical procedure (one hilar and one adrenal metastasis not confirmed histologically), 4/12 further investigations (axillary and liver biopsies, mediastinoscopy, occult colon cancer) and three indications for palliative treatment, in patients who all died within 3 months after FDG-PET.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonic Neoplasms / radionuclide imaging. Decision Making. False Positive Reactions. Female. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis / radionuclide imaging. Male. Mediastinoscopy. Middle Aged. Neoplasm Staging. Neoplasms, Unknown Primary / radionuclide imaging. Palliative Care. Patient Care Planning. Pneumonectomy. Prospective Studies. Retrospective Studies. Tomography, X-Ray Computed. Whole Body Imaging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21087727.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


57. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol; 2006 Oct;45(4):529-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
  • BACKGROUND/AIMS: End-stage liver disease accounts for one in forty deaths worldwide.
  • Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.
  • Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).
  • CONCLUSIONS: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
  • [MeSH-major] Global Health. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality. Liver Cirrhosis / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. World Health Organization


58. Ling CQ, Liu Q, Li DT, Yue XQ, Hou FG, Zhu DZ, Yu CQ, Chen Z, Zhai XF, Yu Y: [Study of a qualitative diagnostic criterion for basic syndromes of traditional Chinese medicine in patients with primary liver cancer]. Zhong Xi Yi Jie He Xue Bao; 2005 Mar;3(2):95-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of a qualitative diagnostic criterion for basic syndromes of traditional Chinese medicine in patients with primary liver cancer].
  • OBJECTIVE: To work out a qualitative diagnostic criterion for basic syndromes of traditional Chinese medicine in patients with primary liver cancer.
  • METHODS: Based on the collection and analysis of related medical literature, clinical investigation, and experts' discussion, a preliminary qualitative diagnostic criterion for basic syndromes of traditional Chinese medicine in patients with primary liver cancer was formulated.
  • RESULTS: The basic syndromes listed in the qualitative diagnostic criterion for basic syndromes in patients with primary liver cancer consisted of two parts: excessive syndromes, including the syndromes of stagnation of qi, blood stasis, excess-heat and dampness, and deficient syndromes, including the syndromes of deficiency of qi, deficiency of blood, deficiency of yin and deficiency of yang.
  • CONCLUSIONS: The qualitative diagnostic criterion for basic syndromes of traditional Chinese medicine in patients with primary liver cancer is coincident with the experts' clinical practice.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Liver Neoplasms / diagnosis. Medicine, Chinese Traditional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Reference Values. Syndrome

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763052.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


59. West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer; 2006 Jun 5;94(11):1751-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.
  • In the last two decades, mortality from primary liver cancer has increased in the UK.
  • We aimed to determine whether the incidence trends for these cancers were similar and in particular if the increasing occurrence of cholangiocarcinoma has continued.
  • We calculated directly age-standardised incidence rates (using the European standard population) by subsite and histological type for all cancers of the liver, gallbladder and biliary tract in England and Wales from 1971 to 2001, using cancer registry data.
  • The incidence of cancers of the liver, gallbladder and biliary tract increased, with the greatest rise, around 12-fold, in intrahepatic bile duct cancers.
  • The rate of liver cell cancer increased by around 45% in males, but by <10% in females.
  • There were marked reductions in the incidence of gallbladder and extrahepatic bile duct cancer.
  • Cholangiocarcinoma increased around 16-fold and became the most common type of primary liver cancer in females, while hepatocellular carcinoma remained the commonest type in males.
  • The age-specific incidence rates showed that intrahepatic bile duct cancer continued to increase throughout the 1990s in those aged 75 and over, while liver cell cancer decreased in the older age groups.
  • In conclusion, there were increases in the incidence of primary liver cancer, which have been particularly dramatic for intrahepatic bile duct cancer, over the last three decades of the 20th century in England and Wales.
  • There has been a halving in the incidence of gallbladder cancer and a reduction of a third in extrahepatic bile duct cancer.
  • [MeSH-major] Biliary Tract Neoplasms / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. England / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Sex Characteristics. Wales / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2005 Apr;54(4):533-9 [15753540.001]
  • [Cites] Health Stat Q. 2004 Autumn;(23):7-17 [15704380.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Gut. 1989 May;30(5):695-700 [2731765.001]
  • [Cites] Popul Trends. 1996 Winter;(86):29-35 [8987096.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Gastrointest Endosc. 1988 May-Jun;34(3):277-8 [3292346.001]
  • (PMID = 16736026.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361300
  •  go-up   go-down


60. Zhang HJ, Yang JJ, Wang WX, Jiang X, Mao YJ, Yang CA, Guo JX: [Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy]. Zhong Xi Yi Jie He Xue Bao; 2008 Sep;6(9):907-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy].
  • OBJECTIVE: To observe and discuss the dynamic changes of interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) and their significance in the patients with primary liver cancer after transarterial chemoembolization (TACE) therapy combined with Jinglong Capsule.
  • METHODS: A total of 48 patients with primary liver cancer, who failed to be treated by major surgery, were randomly divided into two groups: Jinlong Capsule group (TACE therapy plus Jinlong Capsule) and control group (TACE therapy alone).
  • CONCLUSION: Jinlong Capsule can significantly improve the lymphocyte function of the patients with primary liver cancer after TACE.
  • The levels of IL-2 and sIL-2R can be considered as the valuable parameters for evaluating the effects on primary liver cancer, and Jinlong Capsule is helpful for the patients with primary liver cancer.
  • [MeSH-major] Chemoembolization, Therapeutic. Interleukin-2 / blood. Liver Neoplasms / drug therapy. Phytotherapy. Receptors, Interleukin-2 / blood
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Capsules. Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / drug therapy. Drug Therapy, Combination. Drugs, Chinese Herbal / therapeutic use. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782532.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Capsules; 0 / Drugs, Chinese Herbal; 0 / IL2 protein, human; 0 / Interleukin-2; 0 / Receptors, Interleukin-2
  •  go-up   go-down


61. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuya D, Tsuji I: Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer; 2005 Aug 10;116(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan.
  • Although case-control studies suggested that coffee consumption is associated with a decreased risk of liver cancer, no prospective cohort study has been carried out.
  • To examine the association between coffee consumption and the risk of liver cancer, we conducted a pooled analysis of data available from 2 cohort studies in Japan.
  • A self-administered questionnaire about the frequency of coffee consumption and other health habits was distributed to 22,404 subjects (10,588 men and 11,816 women) in Cohort 1 and 38,703 subjects (18,869 men and 19,834 women) in Cohort 2, aged 40 years or more, with no previous history of cancer.
  • We identified 70 and 47 cases of liver cancer among the subjects in Cohort 1 (9 years of follow-up with 170,640 person-years) and Cohort 2 (7 years of follow-up with 284,948 person-years), respectively.
  • We used Cox proportional hazards regression analysis to estimate the relative risk (RR) and 95% confidence interval (CI) of liver cancer incidence.
  • In the subgroup of subjects with a history of liver disease, we found a significant inverse association between coffee consumption and the risk of liver cancer.
  • Our findings support the hypothesis that coffee consumption decreases the risk of liver cancer.
  • Further studies to investigate the role of coffee in prevention of liver cancer among the high-risk population are needed.
  • [MeSH-major] Coffee. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Endoplasmic Reticulum, Smooth. Female. Humans. Japan. Liver Diseases / epidemiology. Male. Middle Aged. Prospective Studies. Risk. Tea

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15756689.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coffee; 0 / Tea
  •  go-up   go-down


62. Zhu K, Moriarty C, Caplan LS, Levine RS: Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control; 2007 Apr;18(3):315-21
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and primary liver cancer: a population-based case-control study in US men.
  • OBJECTIVE: Using the case-control data from the Selected Cancers Study, the authors assessed whether cigarette smoking increases the risk of primary liver cancer in the US.
  • METHODS: Cases were men who were pathologically diagnosed with primary liver cancer during 1984-1988, were 31-59 years old, and lived in the areas covered by eight US cancer registries (n=168).
  • Controls were men without a history of primary liver cancer who were selected by random-digit telephone dialing (n=1910).
  • RESULTS: Relative to non-smokers, the risks of liver cancer were 1.85 (95% confidence interval (CI), 1.05-3.25) and 1.49 (95% CI, 0.83-2.68) for former and current smokers, respectively.
  • CONCLUSIONS: Cigarette smoking may be a factor that contributes somewhat to the occurrence of primary liver cancer among men in the United States, a country with low risk of liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology. Smoking / adverse effects
  • [MeSH-minor] Adult. Case-Control Studies. Humans. Male. Middle Aged. Risk Factors. Socioeconomic Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294291.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Lou HZ, Pan HM, Jin W: [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 May;27(5):393-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation].
  • OBJECTIVE: To investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.
  • METHODS: Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.
  • CONCLUSION: AI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650788.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / aidi herbal drug
  •  go-up   go-down


64. Wang N, Zheng Y, Yu X, Lin W, Chen Y, Jiang Q: Sex-modified effect of hepatitis B virus infection on mortality from primary liver cancer. Am J Epidemiol; 2009 Apr 15;169(8):990-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-modified effect of hepatitis B virus infection on mortality from primary liver cancer.
  • Sex and hepatitis B virus (HBV) infection are both important risk factors for primary liver cancer.
  • The authors assessed the combined effect of sex and HBV infection on liver cancer mortality by calculating 3 interaction measures: the relative risk due to interaction, the attributable proportion of interaction, and the synergy index.
  • After adjustment for potential confounders, the relative risk due to interaction, the attributable proportion of interaction, and the synergy index were 33.27 (95% confidence interval (CI): 22.54, 43.99), 0.59 (95% CI: 0.55, 0.63), and 2.49 (95% CI: 2.13, 2.90), respectively, suggesting a significant synergistic effect of the interaction between sex and HBV infection on liver cancer mortality.
  • HBV infection had a larger impact on liver cancer mortality in men than in women, which may explain at least part of the sex difference in liver cancer risk.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Hepatitis B / epidemiology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Alcohol Drinking / epidemiology. Carrier State / epidemiology. China / epidemiology. Comorbidity. Female. Humans. Longitudinal Studies. Male. Middle Aged. Risk Assessment. Sex Distribution. Sex Factors. Smoking / epidemiology


65. Xu K, Luo HY, Li LN: [Clinical study on comprehensive treatment of primary liver cancer mainly with chinese medicinal perfusion/embolization]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr;25(4):299-302
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on comprehensive treatment of primary liver cancer mainly with chinese medicinal perfusion/embolization].
  • OBJECTIVE: To study the clinical efficacy and adverse reaction of comprehensive therapy mainly with Chinese anti-cancer medicinal perfusion/embolization and assisted with Chinese drug-therapy based on TCM Syndrome Differentiation in treating primary liver cancer.
  • METHODS: Forty-one patients with liver cancer were divided into the treated group and the control group.
  • CONCLUSION: Chinese anti-cancer medicinal perfusion/embolization has affirmative short-term clinical effect in treating primary liver cancer with few adverse reactions, which was tolerable to patients, but its long-term clinical efficacy needs further observation.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892270.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


66. Ribeiro MA Jr, Rodrigues JJ, Habr-Gama A, Chaib E, D'Ipolitto G, Fonseca AZ, Saad WA Jr, Saad WA: Radiofrequency ablation of primary and metastatic liver tumors--4 years experience. Hepatogastroenterology; 2007 Jun;54(76):1170-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of primary and metastatic liver tumors--4 years experience.
  • BACKGROUND/AIMS: Radiofrequency ablation of primary and metastatic liver tumors has been shown to be one of the promising new modalities to treat or to palliate liver tumors.
  • It has been used as a bridge to liver transplantation as well as an approach to recurrent tumors after resection.
  • There were 32 cases of hepatocellular carcinoma, 35 metastases of colorectal cancer and 11 cases of other tumors.
  • All liver segments were compromised specially IV, VII, VIII.
  • CONCLUSIONS: The RFA procedure is safe, can be performed by different ways and in the group of patients who are candidates to liver transplantation, while waiting for the organ.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629064.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


67. Wang JY, Chen Y, Lu W, Wei CJ: [Necessity of prophylactic antibiotics in patients with primary liver cancer undergoing transcatheter arterial chemoembolization: a prospective study]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun;25(6):757-8
Hazardous Substances Data Bank. CEFAZOLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Necessity of prophylactic antibiotics in patients with primary liver cancer undergoing transcatheter arterial chemoembolization: a prospective study].
  • OBJECTIVE: To investigate the necessity of prophylactic administration of antibiotic in patients with primary liver cancer undergoing transcatheter arterial chemoembolization (TACE).
  • CONCLUSION: Prophylactic antibiotics are not necessary for patients with primary liver cancer prior to TACE.
  • [MeSH-major] Antibiotic Prophylaxis. Carcinoma, Hepatocellular / therapy. Cefazolin / therapeutic use. Chemoembolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Catheterization, Peripheral. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958334.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] IHS69L0Y4T / Cefazolin
  •  go-up   go-down


68. Li T, Li ZW, Wen HC: [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Dec;29(12):941-2
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of high doses of thymopentin (10 mg/d) combined with transartery chemoembolization for primary liver cancer.
  • METHODS: Fifty primary liver cancer patients were randomly divided into two groups: therapeutic and control group, and all were treated with transfemoral artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5-Fu 750 mg, CF 300 mg and lipiodol 20 ml.
  • CONCLUSION: Transartery chemoembolization combined with high dose of thymopentin in the treatment for primary liver cancer is effective and safe, and can significantly improve the immune function and the chemotherapy tolerance.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Thymopentin / therapeutic use
  • [MeSH-minor] Adjuvants, Immunologic / adverse effects. Adjuvants, Immunologic / therapeutic use. Adult. Aged. Asthenia / chemically induced. CD4-Positive T-Lymphocytes. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Fever / chemically induced. Fluorouracil / administration & dosage. Humans. Iodized Oil / administration & dosage. Lymphocyte Count. Male. Middle Aged. Nausea / chemically induced. Organoplatinum Compounds / administration & dosage. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478937.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; O3Y80ZF13F / Thymopentin; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Zhang TL, Ma SH, Xiu DR, Song SB, Yuan CH, Jia YM, Gong EC: [The pathological feature of primary hepatic carcinoma on explanted liver and its significance]. Zhonghua Wai Ke Za Zhi; 2010 Jul 1;48(13):964-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The pathological feature of primary hepatic carcinoma on explanted liver and its significance].
  • OBJECTIVE: To investigate the pathological feature of primary hepatic carcinoma and the clinical significance.
  • METHODS: From August 2000 to December 2007, there were 89 patients with cirrhosis and carcinoma of liver who accepted whole liver resection.
  • The whole liver was cut into 10 mm slices to examine the tumor size, number, distribution, capsule, satellite nodes, portal vein tumor thrombi (PVTT).
  • RESULTS: The total of 89 cases included hepatocellular carcinoma in 86 cases and cholangiocarcinoma in 3 cases; 53 cases with multiple tumors and 36 cases with solitary tumor; complete capsule only in 14 cases, no obvious margin in 11 cases, 13 cases had a major tumor in the right lobe and a small tumor in the left lobe; 8 of 25 cases with gross invaded tissue were confirmed by histological examination, 7 of 16 cases with swollen lymph nodes were infiltrated by cancer cells.
  • CONCLUSIONS: The whole explanted liver can completely reflect the characteristics of growth and infiltration of hepatic carcinoma.
  • Attention must be paid to the small cancer lesions in another lobe, distal satellite nodes from major tumor, and tumor thrombi in a small branch of portal vein, which can not be found by imaging, and might influence the curative effectiveness after liver resection or transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Hepatectomy. Humans. Liver / pathology. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054976.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Liang SX, Zhu XD, Lu HJ, Pan CY, Li FX, Huang QF, Wang AY, Chen L, Fu XL, Jiang GL: Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer; 2005 May 15;103(10):2181-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma.
  • BACKGROUND: The purpose of the current study was to evaluate the tolerance and efficacy of hypofractionated three-dimensional conformal radiotherapy (3DCRT) with or without transarterial chemoembolization (TACE) for technically unresectable or medically inoperable primary liver carcinoma (PLC).
  • METHODS: Between April 1999 and August 2003, 128 patients with a clinical diagnosis of PLC received hypofractionated 3DCRT at Cancer Hospital, Guangxi Medical University.
  • Liver cirrhosis of Child-Pugh Grade A was found in 108 patients, and Grade B was found in 20 patients.
  • Radiation-induced liver disease (RILD) developed in 19 (15%) patients, of which 12 had Child-Pugh Grade B liver cirrhosis, and 7 had Grade A.
  • GTV and associated liver cirrhosis were identified by Cox regression analysis as independent predictors for survival (P = 0.044 and 0.015).
  • [MeSH-major] Carcinoma / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemoembolization, Therapeutic. Disease Progression. Dose Fractionation. Female. Follow-Up Studies. Gastroenteritis / etiology. Humans. Liver Cirrhosis / pathology. Liver Diseases / etiology. Male. Middle Aged. Radiation Injuries / etiology. Radiation Tolerance. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812834.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Xu L, Zhou Y, Qiu D: Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese. J Huazhong Univ Sci Technolog Med Sci; 2010 Dec;30(6):815-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese.
  • The study examined the association between calcified liver metastases and the histopathology of the primary colorectal carcinoma in Chinese.
  • The clinical, pathological and CT data were retrospectively analyzed in 210 patients (mean age: 54.2 years) with liver metastases from colorectal carcinoma.
  • All patients had no history of chronic liver diseases and had never received interventional treatments.
  • χ(2)-test was used to analyze the rate of calcification in the liver metastasis from colorectal cancer of different differentiation degrees.
  • Among the 210 cases of liver metastases, 22 patients (10.5%) were found to have calcified liver metastases on CT scan.
  • Two patients with calcified liver metastasis received lumpectomy and developed calcification in recurrent tumors.
  • And the calcification in the newly developed masses was similar to that of their primary counterparts in terms of morphology and distribution.
  • Histopathologically, the primary tumors were well-differentiated adenocarcinoma in 6 cases, moderately-differentiated adenocarcinoma in 10, poorly-differentiated adenocarcinoma in 4 and mucinous adenocarcinoma in 2 among the 22 cases.
  • No statistical correlation was noted between the incidence of calcified liver metastasis and the pathological subtypes and differentiation degrees of the primary colorectal carcinoma.
  • It was concluded that calcified liver metastases may result from colorectal adenocarcinomata of different differentiation degrees or mucinous adenocarcinomata in Chinese population.
  • There is no correlation between calcification of liver metastases and the pathological subtype of the primary colorectal carcinoma in Chinese, which is different from the findings that calcified metastases were associated with colorectal mucinous adenocarcinoma in other ethnic groups.
  • [MeSH-major] Calcinosis / pathology. Colorectal Neoplasms / pathology. Liver / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21181378.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Patiutko IuI, Chuchuev ES, Kotel'nikov AG, Sagaĭdak IV, Badalian KhV: [Synchronous operations in metastatic cancer of the liver]. Khirurgiia (Mosk); 2006;(5):14-7
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous operations in metastatic cancer of the liver].
  • The resection of the liver has been performed in 661 patients including 154 (23.3%) cases of synchronous metastatic cancer of the liver.
  • Among the latter patients primary tumor was removed in one stage with liver resection in 56% cases.
  • Elderly age of the patients, multiple bilobular foci in the liver, size of the foci more than 10 cm, traumatic operations on the primary focus were not contraindications to synchronous operations.
  • Surgical treatment for colorectal cancer should be supplemented with adjuvant chemotherapy.
  • The long-term results demonstrate better survival after synchronous operations for colorectal cancer.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Aged. Female. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858334.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


73. Liu YM, Qin H, Wang CB, Fang XH, Ma QY: Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer. World J Gastroenterol; 2006 Aug 21;12(31):5060-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer.
  • METHODS: The clinical data of 1126 HCC patients who received combined interventional therapy for transcatheter arterial chemoembolization (TACE) before or after hepatectomy, TACE and radio-frequency ablation (RFA), Chinese medicine treatment and biotherapy after TACE or transcatheter arterial infusion (TAI), were reviewed according to the results of their liver function, alpha-fetoprotein, image data, color-ultrasonography finding and survival rate.
  • The liver function, color-ultrasonography finding and alpha-fetoprotein after TACE + RFA, TACE and TAI were compared.
  • There was no significant difference in each index between TACE and RFA or TACE as well as in liver function between TACE and RFA or between TACE and TAI.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic / methods. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kidney / metabolism. Liver / metabolism. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • (PMID = 16937507.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087414
  •  go-up   go-down


74. Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC: Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer; 2007 Apr;43(6):1076-84
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area.
  • This study used a large-scale cancer database in determining the survival prognostic factors among primary liver cancer (PLC) subjects.
  • Particularly, subjects with adenocarcinoma and CC were more likely to die in other metastatic cancer.
  • [MeSH-major] Endemic Diseases / statistics & numerical data. Liver Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adult. Age Distribution. Aged. Carcinoma, Hepatocellular / mortality. Cause of Death. Cholangiocarcinoma / mortality. Female. Humans. Male. Middle Aged. Prognosis. Sex Distribution. Survival Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329095.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


75. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer; 2006 May 15;106(10):2258-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
  • BACKGROUND: Hospitalization for febrile neutropenia (FN) in cancer patients is associated with considerable morbidity, mortality, and cost.
  • The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mortality and prolonged hospitalization in cancer patients with FN.
  • METHODS: The longitudinal discharge database derived from 115 US medical centers was used to study all adult cancer patients hospitalized with FN between 1995 and 2000, comprising a total of 41,779 patients.
  • Primary outcomes included mortality, LOS, and cost per episode.
  • Independent major risk factors for inpatient mortality included invasive fungal infections, Gram-negative sepsis, pneumonia and other lung disease, cerebrovascular, renal, and liver disease.
  • CONCLUSION: Factors associated with increased mortality, LOS, and cost in hospitalized adult cancer patients with FN include patient characteristics, type of malignancy, comorbidities, and infectious complications.
  • [MeSH-minor] Adult. Aged. Confidence Intervals. Female. Follow-Up Studies. Hospitalization / statistics & numerical data. Humans. Incidence. Length of Stay. Logistic Models. Male. Middle Aged. Multivariate Analysis. Registries. Retrospective Studies. Severity of Illness Index. Survival Rate

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society
  • (PMID = 16575919.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Agrin mRNA expression was measured in 11 HCC, 7 CCC, 11 CRCm, and 12 normal liver tissues.
  • Thus, agrin immunohistochemistry may facilitate determination of primary versus metastatic origin in problematic liver cancer cases.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


77. McGlynn KA, Abnet CC, Zhang M, Sun XD, Fan JH, O'Brien TR, Wei WQ, Ortiz-Conde BA, Dawsey SM, Weber JP, Taylor PR, Katki H, Mark SD, Qiao YL: Serum concentrations of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and risk of primary liver cancer. J Natl Cancer Inst; 2006 Jul 19;98(14):1005-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum concentrations of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and risk of primary liver cancer.
  • BACKGROUND: 1,1,1-Trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) exposure has been demonstrated to cause liver tumors in laboratory rodents.
  • DDT's persistent metabolite and environmental degradation product, 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE), has also been associated with liver tumors in laboratory animals.
  • The case group included 168 individuals who developed liver cancer during the trials, and the control group included 385 individuals frequency-matched on age and sex who were alive and well at the end of the study.
  • RESULTS: In multivariable-adjusted models, the risk of developing liver cancer increased with increased serum DDT concentration (OR for quintile 1 versus quintile 5 = 3.8, 95% CI = 1.7 to 8.6, P(trend) = .0024).
  • In contrast, there was no statistically significant association between liver cancer and serum DDE concentration.
  • The association between high serum DDT concentration and liver cancer was stronger among individuals with DDE concentrations below the median value (odds ratio for tertile 3 versus tertile 1 = 3.55, 95% CI = 1.45 to 8.74) than those with concentrations above the median (OR = 1.70, 95% CI = 0.97 to 2.98).
  • A calculation of crude liver cancer risk found that there would be 26 liver cancers per 100 000 persons per year in the lowest quintile of DDT exposure versus 46 liver cancers per 100 000 persons per year in the highest quintile of DDT exposure.
  • CONCLUSIONS: DDT may be a risk factor for liver cancer, particularly among persons with lower DDE concentrations.
  • [MeSH-major] DDT / adverse effects. Dichlorodiphenyl Dichloroethylene / adverse effects. Environmental Exposure / adverse effects. Liver Neoplasms / chemically induced. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinogens. Case-Control Studies. China / epidemiology. Female. Humans. Linear Models. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DDT .
  • Hazardous Substances Data Bank. DDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849683.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 4M7FS82U08 / Dichlorodiphenyl Dichloroethylene; CIW5S16655 / DDT
  •  go-up   go-down


78. Chen JG, Lu JH, Zhu YR, Zhu J, Zhang YH: [A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China]. Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Jul;31(7):721-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China].
  • OBJECTIVE: To study the relationship between hepatitis B virus (HBV) and primary liver cancer (PLC), and to assess the outcome of PLC in the carriers of HBsAg.
  • From January 1, 1977 through December 31, 2007, 12 351 people were enrolled in the cohort, and their occurrence, outcome of PLC and other cancers, together with all the withdrawals due to death were linked to and checked with database from Qidong Cancer Registry and Qidong Vital Registry programs.
  • No relationship was found among carriers and non-carriers for cancer sites such as lung, stomach, esophagus, intestine, pancreas, breast, cervix, bladder, and lymphoma, brain tumor, or leukemia.
  • [MeSH-major] Hepatitis B virus. Liver Neoplasms / epidemiology. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State. Causality. China / epidemiology. Female. Follow-Up Studies. Hepatitis B Surface Antigens. Humans. Incidence. Male. Middle Aged. Prospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162830.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


79. Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, Bramhall S, Mutimer D: Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol; 2007 Sep;33(7):868-73
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence.
  • AIM: To evaluate the risk of recurrence of hepatocellular cancer (HCC) after liver transplantation (LT).
  • METHODS: The clinical records of 104 patients with HCC in the explanted liver were examined.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology. Liver Transplantation. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258882.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


80. Karpan' BM: [Clinical picture and complex treatment of primary and metastatic hepatic cancer]. Lik Sprava; 2006 Apr-May;(3):3-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical picture and complex treatment of primary and metastatic hepatic cancer].
  • The treatment of primary and metastatic hepatic cancer is a complex medical and biological problem conditioned from one side by multiple lesions in the liver and from another side by limited treatment techniques such as: surgical, chemotherapeutical, cryosurgical and radiofrequency ablation.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100176.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


81. Kotb HI, Fouad IA, Fares KM, Mostafa MG, Abd El-Rahman AM: Pharmacokinetics of oral tramadol in patients with liver cancer. J Opioid Manag; 2008 Mar-Apr;4(2):99-104
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of oral tramadol in patients with liver cancer.
  • BACKGROUND: There are no studies reported on pharmacokinetics of opioids in patients with hepatocellular carcinoma, the fifth most common cancer in the world.
  • METHODS: The authors have studied the pharmacokinetic profile of oral tramadol (50 mg) capsule in 20 patients with liver carcinoma (10 with primary carcinoma on top of chronic hepatitis C and 10 with secondary metastatic liver malignancy as a result of other primary) compared with 10 healthy controls.
  • RESULTS: Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).
  • The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].
  • Also, a significant difference in Cmax and Tmax was found between patients with malignant liver and control.
  • Reduced clearance and impaired elimination was significantly observed in patients with liver carcinoma than control.
  • Clearance was reduced to 50 percent of control, and elimination halflife increased up to three folds in patients with primary liver carcinoma than that of control.
  • CONCLUSION: It is recommended to lengthen the dose interval of oral tramadol, if it is to be used in patients with liver cancer for analgesic purposes, to 50 mg every 12 hours as it is proved to be effective and safe.
  • [MeSH-major] Analgesics, Opioid / pharmacokinetics. Liver Neoplasms / physiopathology. Pain, Intractable / drug therapy. Tramadol / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Biological Availability. Humans. Metabolic Clearance Rate. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557166.001).
  • [ISSN] 1551-7489
  • [Journal-full-title] Journal of opioid management
  • [ISO-abbreviation] J Opioid Manag
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 39J1LGJ30J / Tramadol
  •  go-up   go-down


82. Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, Hachiya O, Hirai I, Kimura W: Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg; 2009;16(4):493-501
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic micrometastases around liver metastases from gastric cancer.
  • BACKGROUND/PURPOSE: We aimed to clarify the association between the presence of micrometastases around liver metastases from gastric cancer and the results of hepatic resection.
  • METHODS: Micrometastases around liver metastases were examined microscopically in 31 metastatic liver tumor specimens resected from 17 patients who had undergone hepatic resection for liver metastases from gastric cancer.
  • E-cadherin and MMP-7 expression in the primary gastric tumor, the liver metastases, and the micrometastases were examined immunohistochemically.
  • RESULTS: Hepatic micrometastases were present in around 48% of the liver metastases, accounting for 59% of the patients.
  • The tumor recurrence rate in the remnant liver after hepatic resection was significantly higher, and survival significantly poorer, in patients with such micrometastases than in those without.
  • Micrometastases tended to appear around the liver metastases that had reduced E-cadherin expression.
  • CONCLUSIONS: About half of the hepatic metastases from gastric cancer had seeded off micrometastases, and the presence of these micrometastases was associated with a poorer result of hepatic resection.
  • Reduced E-cadherin expression in metastatic liver tumors may be associated with the development of micrometastases.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cadherins / metabolism. Chemotherapy, Adjuvant. Disease Progression. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Portal Vein / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360371.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cadherins; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


83. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol; 2008 Jun;9(6):533-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
  • BACKGROUND: JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell-cycle abnormalities and epidermal growth factor receptor (EGFR)-ras pathway activation.
  • We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver cancer.
  • METHODS: Between Jan 4, 2006, and July 4, 2007, 14 patients with histologically confirmed refractory primary or metastatic liver tumours (up to 10.9 cm total diameter) that were amenable to image-guided intratumoral injections were enrolled into this non-comparative, open-label, phase I dose-escalation trial (standard 3x3 design; two to six patients for each dose with 12-18 estimated total patients).
  • Adverse event-monitoring according to the National Cancer Institute Common Toxicity Criteria (version 3) and standard laboratory toxicity grading for haematology, liver and renal function, coagulation studies, serum chemistry, and urinalysis were done.
  • The primary aims were to ascertain the maximum-tolerated dose (MTD) and safety of JX-594 treatment.
  • FINDINGS: Of 22 patients with liver tumours who were assessed for eligibility, eight patients did not meet inclusion criteria.
  • Therefore, 14 patients, including those with hepatocellular, colorectal, melanoma, and lung cancer, were enrolled.
  • INTERPRETATION: Intratumoral injection of JX-594 into primary or metastatic liver tumours was generally well-tolerated.
  • [MeSH-major] Liver Neoplasms / therapy. Oncolytic Virotherapy. Oncolytic Viruses. Vaccinia virus
  • [MeSH-minor] Adult. Aged. Female. Granulocyte-Macrophage Colony-Stimulating Factor / biosynthesis. Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Humans. Hyperbilirubinemia / etiology. Immunohistochemistry. Male. Middle Aged. Positron-Emission Tomography. Poxviridae Infections / etiology. Time Factors. Tomography, X-Ray Computed. Treatment Failure. Treatment Outcome. Virus Replication


84. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • [MeSH-major] Chromosome Aberrations. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Kruschewski M, Pohlen U, Hotz HG, Ritz JP, Kroesen AJ, Buhr HJ: [Results of multivisceral resection of primary colorectal cancer]. Zentralbl Chir; 2006 Jun;131(3):217-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of multivisceral resection of primary colorectal cancer].
  • BACKGROUND: In about 10 % of all patients with colorectal cancer, the primary invention already discloses adhesions or infiltration of adjacent organs.
  • METHOD: Between 1/95 and 6/04, we analyzed all patients with progressive primary colorectal cancer, who underwent multivisceral surgery with en bloc resection of at least one other organ.
  • RESULTS: A total of 1 001 patients with colorectal cancer underwent surgery.
  • Tumor perforation was seen in 17 % of patients with colon cancer and 16 % with rectal cancer.
  • Resection of the inner genitals was most frequent in both colon and rectal cancer (26 and 84 %) followed by small bowel resection (21 %) and partial bladder resection (19 %).
  • Other organs play a secondary role in rectal cancer while partial bladder resection (20 %) and abdominal wall resection (14 %) is observed more frequently in colon cancer.
  • Resection of parenchymatous organs (kidney, suprarenal gland, spleen, pancreas, liver) and others like the stomach is quite rare in colon cancer.
  • Actual tumor infiltration (T4 situation) was observed in 51 % of patients with colon cancer and in 64 % of those with rectal cancer.
  • Local R0 resection (97 vs. 96 %) was successfully performed in nearly all colon and rectal cancer patients.
  • The surgical major complication rate was 9 % in colon cancer and 19 % in rectal cancer.
  • CONCLUSION: Multivisceral en-bloc resection enables local R0 resection in the majority of cases with primary colorectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Survival Rate. Viscera / pathology. Viscera / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739062.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Febbraro I, Manetti G, Balestrieri P, Zippi M: Rectal cancer or rectal chancre? Beware of primary syphilis. Dig Liver Dis; 2008 Jul;40(7):579-81
Hazardous Substances Data Bank. PENICILLIN G .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer or rectal chancre? Beware of primary syphilis.
  • The number of reported cases of primary syphilis is increasing especially among this group of people [Goh BT.
  • We herein describe a case of a young man with a primary syphilitic rectal localization mimicking rectal cancer.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Penicillin G / therapeutic use. Sigmoidoscopy. Syphilis / diagnosis. Syphilis Serodiagnosis / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313998.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; Q42T66VG0C / Penicillin G
  •  go-up   go-down


87. Estrada-Sánchez G, Ochoa-Carrillo FJ, Altamirano-Ley J: [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer]. Cir Cir; 2008 Jul-Aug;76(4):279-86
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
  • BACKGROUND: Of women between 15 and 29 years of age, 13.6% will die from breast cancer.
  • For women between 30 and 64 years of age, 19% will die from breast cancer.
  • METHODS: We studied 1728 oncological patients and 295 patients were included, 293 with breast cancer (17%) and two patients with primary breast lymphoma (0.1%).
  • SUVmax for the primary tumor was 4.2 +/- 2.6 SD.
  • Mean SUVmax for patients with primary breast lymphoma were 3.2 and 1.4.
  • Sites of metastases were lymph nodes in the neck (4.4% SUVmax 2.7), internal mammary lymph nodes (5% SUVmax 5.3), mediastinum (8.3% SUVmax 5.0), retroperitoneal (6 % SUVmax 5.4), ipsilateral axilla (94% SUVmax 4.5), contralateral axilla (4.4% SUVmax 2.8), pectoral muscle (10.2% SUVmax 2.6), pleura (4.4% SUVmax 3.9), lung (32.3% SUVmax 2.9), liver (19.1% SUVmax 4.5), bone (36.7%), adrenal gland (4.4% SUVmax 2.4), brain (4.4%), spleen and contralateral breast, one case each.
  • The incidence of a second primary was 4.7%, 2.1% ovarian, 1.4% lung, 0.3% lymphoma, 0.3% endometrium, 0.3% pancreas and 0.3% thyroid.
  • CONCLUSIONS: Mean SUVmax for the primary tumor was similar to that reported in the literature.
  • [MeSH-minor] Adult. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radiography. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Cost-Benefit Analysis. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Hyperplasia. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Mammography. Neoplasms, Multiple Primary / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Thymus Gland / pathology. Thymus Gland / radionuclide imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778536.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Erichsen R, Jepsen P, Jacobsen J, Nørgaard M, Vilstrup H, Sørensen HT: Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol; 2008 Feb;20(2):104-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004.
  • OBJECTIVES: Changes, over the last 20 years, in the diagnostic procedures and treatment of primary liver cancer (PLC) and liver metastases of unknown origin (LMUO) may have affected the clinical course of both cancers.
  • [MeSH-major] Liver Neoplasms / epidemiology. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Denmark / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188029.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


89. Manba N, Nashimoto A, Yabusaki H, Nakagawa S, Nomura T, Maruyama S, Takii Y, Tsuchiya Y, Tanaka O: [Evaluation of hepatic resection for synchronous liver metastasis from gastric cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2016-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of hepatic resection for synchronous liver metastasis from gastric cancer].
  • To evaluate the effect of hepatic resection for synchronous liver metastasis from gastric cancer, the clinicopathological factors of gastric cancer, the size and number of liver metastasis and surgical procedures for liver metastasis were studied.
  • The number of liver metastasis: 27 patients had 1 lesion, 9 patients had 2 lesions, and 13 patients had more than 3 lesions.
  • Univariate analysis pointed out several prognostic factors such as histological type of primary lesion, T-factor, lymph node metastasis, the number and size of liver metastasis and the procedures for hepatic resection.
  • Multivariate analysis revealed that two factors of N0 or N1 in lymph node metastasis and partial resection of liver metastasis were favorable independent prognostic factors (p=0.0108 and p=0.0192).
  • In conclusion, N0 and N1 state and partial resection of the liver metastasis would be good candidates for gastrectomy and synchronous resection of liver metastatic lesions.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / secondary. Neoplasms, Multiple Primary / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastrectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037309.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


90. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


91. Hemminki K, Mousavi SM, Brandt A, Ji J, Sundquist J: Liver and gallbladder cancer in immigrants to Sweden. Eur J Cancer; 2010 Mar;46(5):926-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver and gallbladder cancer in immigrants to Sweden.
  • BACKGROUND: The changes of cancer incidence upon immigration can be used as an estimator of environmental influence on cancer risk.
  • We studied site-specific liver and biliary cancers in first-generation immigrants to Sweden with an aim to search for aetiological clues and to find evidence for indigenous incidence rates.
  • MATERIAL AND METHODS: We used the nation-wide Swedish Family-Cancer Database to calculate standardised incidence ratios (SIRs) in immigrants compared to native Swedes.
  • RESULTS: A total of 1428 cancers were identified in immigrants whose median ages (years) at immigration were 27 for men and 26 for women and whose median diagnostic ages were 64 and 66, respectively.
  • The highest SIRs of 6.7 for primary liver cancer were observed for men from East Asia and sub-Saharan Africa.
  • For gallbladder cancer, only women from the Indian subcontinent (3.84) and Chile (2.34) had increased risk while some Northern European immigrants showed decreased risks.
  • CONCLUSIONS: Primary liver cancer was increased in immigrants from endemic regions of hepatitis B virus infection but also from large regions lacking cancer incidence data, North Africa, Asian Arab countries, Turkey and previous Yugoslavia; these are probably intermediary risk regions for this infection.
  • The increase in gallbladder cancer in Chileans and Indians suggests that some persistent damage was inflicted before emigration, characterisation of which will be a challenge for aetiological studies.
  • [MeSH-major] Emigrants and Immigrants / statistics & numerical data. Gallbladder Neoplasms / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. Sweden / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20064704.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Koyama M, Tanaka H, Matsueda K, Muto T: Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis; 2009 Jun;11(5):464-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer.
  • OBJECTIVE: Preoperative use of emission tomography with(18)F-fluorodeoxyglucose (FDG-PET) in patients with primary colorectal cancer remains controversial.
  • This study evaluated the additional value of FDG-PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.
  • METHOD: Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole-body FDG-PET.
  • Results of FDG-PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases.
  • Liver metastases were present in 22 patients.
  • CONCLUSION: Preoperative FDG-PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637927.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


93. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS: Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med; 2007;5:15
Hazardous Substances Data Bank. YTTRIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.
  • BACKGROUND: Treatment records and follow-up data on 40 patients with primary and metastatic liver malignancies who underwent a single whole-liver treatment with Y-90 resin microspheres (SIR-Spheres Sirtex Medical, Lake Forest, IL) were retrospectively reviewed.
  • The objective of the study was to evaluate the anatomic and physiologic determinants of radiation dose distribution, and the dose response of tumor and liver toxicity in patients with liver malignancies who underwent hepatic arterial Y-90 resin microsphere treatment.
  • METHODS: Liver and tumor volume calculations were performed on pre-treatment CT scans.
  • Fractional tumor and liver flow characteristics and lung shunt fractions were determined using hepatic arterial Tc-99m MAA imaging.
  • Liver toxicity was assessed clinically and by liver function tests.
  • RESULTS: Of the 40 patients, 5 had hepatocellular cancer (HCC), and 35 had metastatic liver tumors (15 colorectal cancer, 10 neuroendocrine tumors, 4 breast cancer, 2 lung cancer, 1 ovarian cancer, 1 endometrial cancer, and 2 unknown primary adenocarcinoma).
  • Tumor volumes ranged from 15.0 to 984.2 cc (mean: 294.9 cc) and tumor to normal liver uptake ratios ranged from 2.8 to 15.4 (mean: 5.4).
  • Liver absorbed doses ranged from 0.7 to 99.5 Gy (mean: 17.2 Gy).
  • None of the patients had clinical venoocclusive disease or therapy-induced liver failure.
  • CONCLUSION: Doses up to 99.5 Gy to uninvolved liver are tolerated with no clinical venoocclusive disease or liver failure.
  • The utilization of MAA-based imaging techniques to determine tumor and liver blood flow for clinical treatment planning and the calculation of administered activity may improve clinical outcomes.
  • [MeSH-major] Liver / metabolism. Liver / pathology. Liver Neoplasms / therapy. Microspheres. Yttrium / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Toll-Like Receptors / metabolism. Treatment Outcome. Yttrium Radioisotopes

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2000 Oct;41(10):1673-81 [11037997.001]
  • [Cites] Phys Med Biol. 2001 Feb;46(2):487-98 [11229728.001]
  • [Cites] Arch Surg. 2007 Jul;142(7):675-82 [17638807.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1209-11 [16818957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):333-7 [11379303.001]
  • [Cites] Ann Oncol. 2001 Dec;12(12):1711-20 [11843249.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20 [12029557.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] J Vasc Interv Radiol. 2004 Apr;15(4):335-45 [15064336.001]
  • [Cites] Jpn J Clin Oncol. 2004 Sep;34(9):532-9 [15466827.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Aug;124(4):596-9 [1163723.001]
  • [Cites] J Surg Oncol. 1978;10(4):327-36 [692139.001]
  • [Cites] Arch Pathol Lab Med. 1980 Nov;104(11):584-8 [6893535.001]
  • [Cites] J Surg Oncol. 1982 Jul;20(3):151-6 [7201051.001]
  • [Cites] Radiology. 1989 Sep;172(3):857-60 [2549567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):619-23 [2318695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):463-7 [2061122.001]
  • [Cites] Aust N Z J Surg. 1992 Feb;62(2):105-10 [1586298.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):70-3 [8271063.001]
  • [Cites] Br J Radiol. 1994 Feb;67(794):136-9 [8130973.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):994-9 [7947110.001]
  • [Cites] Br J Radiol. 1997 Aug;70(836):823-8 [9486047.001]
  • [Cites] J Surg Oncol. 2004 Nov 1;88(2):78-85 [15499601.001]
  • [Cites] Arch Surg. 1964 Aug;89:244-9 [14160151.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200-8 [14243011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63 [15590187.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jul;16(7):911-35 [16002500.001]
  • (PMID = 17359531.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toll-Like Receptors; 0 / Yttrium Radioisotopes; 58784XQC3Y / Yttrium
  • [Other-IDs] NLM/ PMC1845138
  • [General-notes] NLM/ Original DateCompleted: 20070802
  •  go-up   go-down


94. Méndez-Sánchez N, Villa AR, Vázquez-Elizondo G, Ponciano-Rodríguez G, Uribe M: Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol; 2008 Jul-Sep;7(3):226-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality trends for liver cancer in Mexico from 2000 to 2006.
  • Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with an estimated incidence of half a million new cases per year around the world.
  • Furthermore, HCC is the third greatest cause of cancer-related death in the world, and most of these deaths are registered in developing countries.
  • Causes of death related to HCC were selected in accordance with the International Classification of Diseases, 10th Revision, Liver Cancer (C22.0, C22.7, C22.9).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Mexico. Middle Aged. Mortality / trends. Sex Distribution. Sex Factors. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753989.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


95. Gleiberman AS, Encinas JM, Mignone JL, Michurina T, Rosenfeld MG, Enikolopov G: Expression of nestin-green fluorescent protein transgene marks oval cells in the adult liver. Dev Dyn; 2005 Oct;234(2):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nestin-green fluorescent protein transgene marks oval cells in the adult liver.
  • Oval cells, which become apparent in the liver after chronic injury, serve as bipotent progenitors for differentiated hepatocytes and cholangiocytes.
  • We found that, in the liver of adult transgenic mice in which expression of green fluorescent protein (GFP) is driven by regulatory elements of the nestin gene, the GFP signal marks a subpopulation of small epithelial cells that meet the criteria for oval cells, including morphology, localization, antigenic profile, and reactivity in response to injury.
  • In the regenerating and developing liver, we also found nestin-GFP-positive cells that express hepatocyte markers; such cells may correspond to transiently appearing differentiating progeny of oval cells.
  • During development, GFP-expressing cells in the liver emerge relatively late, after the appearance of differentiated hepatocytes and cholangiocytes.
  • Our results suggest that nestin-GFP cells in the liver correspond to a specialized cell type whose primary function may be to serve as a reserve for adult liver epithelial cell types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • [Cites] Dev Dyn. 1996 Jul;206(3):272-90 [8896983.001]
  • [Cites] Differentiation. 1993 Dec;55(1):19-26 [8299877.001]
  • [Cites] Development. 1998 Aug;125(16):3087-100 [9671582.001]
  • [Cites] Dev Biol. 1999 Jan 15;205(2):309-21 [9917366.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] J Cell Biol. 2004 Dec 6;167(5):935-44 [15569711.001]
  • [Cites] Science. 1998 Jan 23;279(5350):514-9 [9438837.001]
  • [Cites] Neuron. 1994 Jan;12(1):11-24 [8292356.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1326-36 [7694468.001]
  • [Cites] Differentiation. 1990 Oct;45(1):29-37 [2292360.001]
  • [Cites] Histochemistry. 1990;94(2):179-86 [2193005.001]
  • [Cites] Acta Anat (Basel). 1990;137(2):141-5 [2180247.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Cell Res. 1989 Sep;184(1):228-34 [2477266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Sep;81(17):5523-7 [6206499.001]
  • [Cites] Histochemistry. 1984;80(4):401-7 [6203880.001]
  • [Cites] Int J Cancer. 1983 Jul 15;32(1):85-92 [6190767.001]
  • [Cites] Biull Eksp Biol Med. 1982 Apr;93(4):79-82 [7082808.001]
  • [Cites] Int J Cancer. 1977 Sep 15;20(3):388-93 [71280.001]
  • [Cites] Adv Cancer Res. 1971;14:295-358 [4107670.001]
  • [Cites] Biull Eksp Biol Med. 1968 Feb;65(2):45-7 [4173532.001]
  • [Cites] Exp Cell Res. 2004 Nov 15;301(1):91-102 [15501450.001]
  • [Cites] Nat Biotechnol. 2004 Sep;22(9):1115-24 [15322557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11881-8 [12902545.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] Neuroreport. 2000 Jun 26;11(9):1991-6 [10884058.001]
  • [Cites] Mol Cell Neurosci. 2001 Feb;17(2):259-73 [11178865.001]
  • [Cites] J Neurosci. 2001 Jun 1;21(11):3895-903 [11356877.001]
  • [Cites] Wound Repair Regen. 2001 Nov-Dec;9(6):467-82 [11896989.001]
  • [Cites] Nat Rev Genet. 2002 Jul;3(7):499-512 [12094228.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):405-9 [12468240.001]
  • [Cites] J Comp Neurol. 2004 Feb 9;469(3):311-24 [14730584.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9958-61 [12904579.001]
  • [Cites] Hepatology. 2003 Mar;37(3):632-40 [12601361.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Mar;35(3):267-71 [12531236.001]
  • (PMID = 16127706.001).
  • [ISSN] 1058-8388
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK018477-33; United States / NIDDK NIH HHS / DK / R01 DK018477; United States / NINDS NIH HHS / NS / R01 NS032764; United States / NIDDK NIH HHS / DK / R01 DK018477-33
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Adhesion Molecules; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / alpha-Fetoproteins; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS66703; NLM/ PMC2751636
  •  go-up   go-down


96. Clements D, Dhruva Rao P, Ramanathan D, Adams R, Maughan TS, Davies MM: Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis; 2009 Oct;11(8):845-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
  • OBJECTIVE: The management of the asymptomatic primary in stage IV colorectal cancer presents a dilemma.
  • Nonresectional management of the primary is associated with the risks of obstruction, perforation or haemorrhage.
  • We reviewed our nonoperatively managed patients with colorectal liver metastases in order to identify the percentage of patients requiring urgent operative interventions for symptoms related to the primary.
  • There were no similarities between these three patients in terms of age, sex, site or stage of primary, volume of liver metastases, and alkaline phosphatase (ALP) or carcinoembryonic antigen (CEA) levels.
  • CONCLUSION: Of 37 patients initially treated palliatively for stage IV colorectal cancer, 92% required no surgical treatment of their primary.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Mar;12(3):267; author reply 267-8 [20041926.001]
  • (PMID = 19175637.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


97. Yarom N, Marginean C, Moyana T, Gorn-Hondermann I, Birnboim HC, Marginean H, Auer RC, Vickers M, Asmis TR, Maroun J, Jonker D: EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biol Ther; 2010 Sep 1;10(5):416-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR expression variance in paired colorectal cancer primary and metastatic tumors.
  • BACKGROUND: Previous studies indicate that drugs targeting the Epidermal Growth Factor Receptor (EGFR) signaling pathways can induce objective responses, prolong time to progression and improve survival of patients with metastatic colorectal cancer (mCRC).
  • EGFR expression in the primary tumour may not predict response to these agents and data is conflicting regarding the correlation of EGFR expression in the primary tumour with the metastatic site.
  • OBJECTIVES: The goal of this study is to correlate tumour EGFR expression between primary and liver metastatic sites, and to assess the mutational status in the EGFR kinase domain.
  • METHODS: This is a single center retrospective study of patients who underwent surgical resection of CRC, for whom paired paraffin-embedded tissue blocks of primary tumours and resected liver metastases were available.
  • EGFR was detectable in 96.6% of the primary samples and in 89.7% of the metastatic samples.
  • Perfect concordance in the intensity score between the primary and the metastases was found in 46.5% of the cases.
  • Overall survival did not correlate with either EGFR expression in the primary tumour, or with EGFR expression in the metastasis.
  • CONCLUSIONS: In this analysis, EGFR expression in the primary tumor site was not predictive of its level in the metastasis.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Liver Neoplasms / secondary. Neoplasm Metastasis. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Biomarkers, Tumor. Female. Fluorescent Antibody Technique. Gene Expression. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Mutation. Prognosis. Retrospective Studies


98. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH: The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum; 2009 Jan;52(1):23-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.
  • PURPOSE: This study was designed to investigate the outcome of "the liver-first" approach in patients with locally advanced rectal cancer and synchronous liver metastases.
  • METHODS: Patients with locally advanced rectal cancer and synchronous liver metastases were primarily treated for their liver metastases.
  • One patient had liver resection without neoadjuvant chemotherapy followed by chemoradiotherapy.
  • Eighteen patients underwent partial liver resection and subsequent chemoradiotherapy for the rectal cancer.
  • One patient underwent in one session a partial liver resection and a low anterior resection.
  • CONCLUSIONS: This is the first sizable report on the "liver-first approach" demonstrating that it may be considered the preferred treatment schedule for patients with locally advanced rectal cancer and synchronous liver metastases.
  • It allows most patients to undergo curative resections of both metastatic and primary disease and can avoid useless rectal surgery in patients with incurable metastatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Laparotomy. Male. Middle Aged. Neoadjuvant Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273952.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Lao XM, Zhang YQ, Jin X, Lin XJ, Guo RP, Li GH, Li JQ: Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology; 2006 Jan-Feb;53(67):128-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases.
  • BACKGROUND/AIMS: Primary clear cell carcinoma of the liver (PCCCL) is a subgroup of hepatocellular carcinoma.
  • The differentiation degree ranged from grade 1 to 3, liver cirrhosis or/and chronic hepatitis was present in paratumorous tissues.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506391.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


100. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL: Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys; 2006 Jun 1;65(2):426-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance.
  • PURPOSE: To identify risk factors relevant to radiation-induced liver disease (RILD) and to determine the hepatic tolerance to radiation.
  • METHODS AND MATERIALS: The data of 109 primary liver carcinomas (PLC) treated with hypofractionated three-dimensional conformal radiation therapy (3D-CRT) were analyzed.
  • (1) Mean dose to normal liver (MDTNL) of 23 Gy was tolerable. (2) For cumulative dose-volume histogram, the tolerable volume percentages would be less than: V5 of 86%, V10 of 68%, V15 of 59%, V20 of 49%, V25 of 35%, V30 of 28%, V35 of 25%, and V40 of 20%. (3) Tolerable MDTNL could be estimated by MDTNL (Gy) = -1.686 + 0.023 * normal liver volume (cm3).
  • [MeSH-major] Liver / radiation effects. Liver Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiation Tolerance / physiology. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular. Dose Fractionation. Female. Humans. Liver Cirrhosis / etiology. Liver Cirrhosis / pathology. Logistic Models. Male. Maximum Tolerated Dose. Middle Aged. Multivariate Analysis. Neoplasm Staging. ROC Curve. Risk Factors

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690430.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement